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Abstract 
Acute myeloid leukemia (AML) is an aggressive malignant disease characterized by poor 
patient outcome and suboptimal front-line chemotherapy. To identify novel anti-AML compounds, a 
high-throughput screen of a natural products library (n=800) was performed. This screen was 
performed against the AML cell line (TEX), which has several properties of leukemia stem cells, the 
cells responsible for disease pathophysiology and patient relapse.  Here, avocatin B was identified as 
a potent and novel anti-leukemia agent. Avocatin B, at concentrations as high as 20µM, had no effect 
on normal peripheral blood stem cell viability.  In contrast, it induced death of primary AML cells 
with an EC50 of 1.5-5.0 µM. Selective toxicity towards a functionally defined subset of primitive 
leukemia cells was also demonstrated. Avocatin B (3µM) reduced clonogenic growth of AML 
progenitor cells with no effect on clonogenic growth of normal hematopoietic stem cells. Further, 
treatment of primary AML cells with avocatin B (3µM) diminished their ability to engraft into the 
bone marrow of pre-conditioned, NOD/SCID mice (t18=6.5; p<0.001). Together, these results confirm 
that avocatin B is a novel anti-AML agent with selective toxicity towards leukemia and leukemia 
stem cells.  
Mechanistically, avocatin B induced reactive oxygen species (ROS)-dependent leukemia cell 
apoptosis that was characterized by the release of mitochondrial proteins, cytochrome c and apoptosis 
inducing factor (AIF).  Cytochrome c and AIF were detected in the cytosol of avocatin B treated TEX 
cells by flow cytometry. Avocatin B-induced apoptosis, as measured by the Annexin V/Propidium 
iodide assay, DNA fragmentation and PARP cleavage, and was abolished in the presence of anti-
oxidants confirming the functional importance of ROS. Next, we further evaluated the role of 
mitochondria in avocatin B-induced apoptosis. First, we generated leukemia cells lacking 
mitochondria by successive culturing in media containing ethidium bromide. The drastic (>80%) 
reduction in mitochondria was confirmed by nonyl acridine orange staining and flow cytometry and a 
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near absence of the mitochondria specific proteins ANT and ND1, as measured by Western blotting. 
Avocatin B’s activity was abolished in leukemia cells lacking mitochondria. Next, we tested avocatin 
B in cells engineered to lack CPT1, the enzyme that facilitates transport of 16-20 carbon lipids into 
mitochondria. Avocatin B’s activity was abolished in cells with reduced CPT1 expression (>70% as 
measured by qPCR analysis). To further confirm the importance of CPT1 in avocatin B-induced 
death, we chemically inhibited CPT1 with etomoxir. Avocatin B’s activity was blocked in the 
presence of etomoxir, further demonstrating that avocatin B accumulates in mitochondria.  
Since avocatin B is a lipid that targets mitochondria and that mitochondria can oxidize fatty 
acids for energy, we next assessed the impact of avocatin B on fatty acid oxidation, using the 
Seahorse Bioanalyzer. Avocatin B inhibited leukemia cell fatty acid oxidation (>40% reduction in 
oxygen consumption at 10µM) and this occurred at a 10-fold less concentration than etomoxir, the 
standard experimental molecule used to probe this pathway.  Further, avocatin B treatment  resulted 
in a 50% reduction in levels of NADPH, an important co-factor generated during fatty acid oxidation 
that participates in catabolic processes during cell proliferation.  
Additionally, we demonstrated that autophagy was functionally important for avocatin B 
induced leukemia cell death. We reported increased autophagic activity through confocal microscopy 
and Western Blotting of autophagy specific proteins LC3B, ATG7, SQSTM1(p62) and BNIP3L(Nix). 
To further confirm the importance of autophagy in avocatin B-induced death, we generated cells with 
reduced ATG7, the protein involved in autophagosome formation. Avocatin B’s activity was 
abolished in these cells demonstrating that autophagy was essential for avocatin B’s activity.  
These results show that avocatin B accumulates in mitochondria to inhibit fatty acid oxidation 
and reduce NADPH to result in ROS-mediated activation of autophagy and apoptosis in leukemia 
cells. This highlights a novel AML-therapeutic strategy by which mitochondria are targeted to impair 
cellular metabolism leading directly to AML cell death.  
 v 
 
Acknowledgements 
First and foremost, I would like to thank my supervisor, Dr. Paul A. Spagnuolo, for his 
continual guidance and support. The accomplishments that I have achieved over the past two years 
serve as a testament of his exemplary mentorship. It has been an honour and privilege to have a 
mentor that I can rely on for both advice and support.  I would like to thank my advisory committee 
members, Dr. Jonathan Blay and Dr. Jamie Joseph, for their feedback and input throughout my 
masters. I would like to acknowledge the numerous collaborators who have contributed to the success 
of this thesis: Dr. Schimmer, Dr. Quadrilatero, Dr. Joseph, Dr. Minden, Elliott McMillan, Andrew 
Mitchell, Elena Kreinin, and Thomas Hanlon. Many thanks to Sarah Rae for her patience and 
kindness when dealing with my administrative requests. Special thanks to Dr. Murray Cutler Jr., our 
token post-doc, whose advice and feedback have been invaluable. I would also like to acknowledge 
and thank Roger Chen, Marina Jalal and Samih Alqawlaq, for both their friendship and their 
contributions to the success of the project (but will never be formally acknowledged). I would like to 
thank and acknowledge my lab mates, Leonard Angka, Sarah-Grace Rota and Kevin the fish, for not 
only being supportive teammates but being my family away from home. I am grateful to have spent 
almost every day of the last two years with my best friends. Thank you to #loveisonyourside for being 
the perfect escape to long and unsuccessful days in the lab. Together we have built some 
unforgettable memories and others that ought to be forgotten. Thank you to the all the graduate 
students at the School of Pharmacy who welcomed me into their community. I am thankful for your 
friendship and wish you all success. Thank you Angela Millson for all your love and support. I am 
eternally grateful to have met you. I am also thankful that you passed the OSCE.  Last but not least, 
thank you to my family for their continual love and support. My successes are yours.  
 vi 
 
Table of Contents 
AUTHOR'S DECLARATION ............................................................................................................... ii 
Abstract ................................................................................................................................................. iii 
Acknowledgements ................................................................................................................................ v 
Table of Contents .................................................................................................................................. vi 
List of Figures ....................................................................................................................................... ix 
Chapter 1 : General Introduction ............................................................................................................ 1 
1.1 Acute myeloid leukemia (AML) .................................................................................................. 1 
1.1.1 Treatment ............................................................................................................................... 2 
1.2 Leukemia stem cells (LSCs) ......................................................................................................... 3 
1.3 Metabolic alterations in cancer cells ............................................................................................ 4 
1.3.1 Metabolic alterations in leukemia cells ................................................................................. 7 
1.4 Leukemia cell death ...................................................................................................................... 8 
1.4.1 Apoptosis ............................................................................................................................... 8 
1.4.2 Autophagy ........................................................................................................................... 11 
1.5 Avocatin B .................................................................................................................................. 15 
Chapter 2 : Objectives and Hypothesis ................................................................................................ 17 
Chapter 3 : Methods ............................................................................................................................. 18 
3.1 Methods ...................................................................................................................................... 18 
3.1.1 Cell culture .......................................................................................................................... 18 
3.1.2 CD34+ cell enrichment ........................................................................................................ 19 
3.1.3 Flow cytometry .................................................................................................................... 19 
3.1.4 Palmitate, malonyl-CoA, acetyl-CoA, and oleic acid study ................................................ 21 
3.1.5 Western blotting .................................................................................................................. 21 
3.1.6 Cell growth and viability ..................................................................................................... 23 
3.1.7 Functional stem cell assays ................................................................................................. 24 
3.1.8 High-throughput screen ....................................................................................................... 24 
3.1.9 Drug combination studies .................................................................................................... 25 
3.1.10 mRNA detection ................................................................................................................ 25 
3.1.11 Assessment of fatty acid oxidation and mitochondrial respiration .................................... 25 
3.1.12 NADPH detection .............................................................................................................. 26 
 vii 
 
3.1.13 Apoptosis measurements ................................................................................................... 26 
3.1.14 AIF and cytochrome c detection ........................................................................................ 27 
3.1.15 Hypoxia experiments ......................................................................................................... 27 
3.1.16 Autophagy detection .......................................................................................................... 27 
3.1.17 RNAi knockdown of Atg7 and p62 ................................................................................... 28 
3.1.18 Interrogation of chemogenomics database ........................................................................ 28 
3.1.19 Statistical analysis ............................................................................................................. 28 
Chapter 4 Results .................................................................................................................................. 30 
4.1.1 A high-throughput screen for novel anti-AML compounds identifies avocatin B .............. 30 
4.1.2 Avocatin B is selectively toxic toward leukemia progenitor and stem cells ....................... 30 
4.1.3 Avocatin B’s selective cytotoxicity correlates with CD33+/CD34+ expression ................. 33 
4.1.4 Avocatin B induces mitochondria-mediated apoptosis ....................................................... 34 
4.1.5 Avocatin B’s activity involves the fatty acid metabolism pathway..................................... 37 
4.1.6 Avocatin B inhibits fatty acid oxidation .............................................................................. 41 
4.1.7 Inhibiting fatty acid oxidation results in reduced NADPH and elevated ROS .................... 42 
4.1.8 Assessing PPARα’s role in avocatin B mediated leukemia cell death ................................ 45 
4.1.9 Mitochondria and CPT1 are functionally important for avocatin B-induced death ............ 46 
4.1.10 Avocatin B activates autophagy ........................................................................................ 49 
4.1.11 Autophagy is functionally important for avocatin B-induced death.................................. 51 
4.1.12 Establishing a methodology for the long-term culture of primary AML samples ............. 52 
4.2 Supplemental figures .................................................................................................................. 53 
Chapter 5 : Discussion .......................................................................................................................... 59 
5.1 Avocatin B’s selectivity ............................................................................................................. 59 
5.2 Mechanism of action .................................................................................................................. 62 
5.2.1 Decreased levels of NADPH cause increases in ROS ......................................................... 63 
5.2.2 Decreased NADPH and increased levels of ROS cause mitochondria-mediated apoptosis 64 
5.2.3 Avocatin B’s effect on the fatty acid biosynthesis pathway ................................................ 64 
5.2.4 Palmitate supplementation rescues TEX cells from avocatin B induced cell death ............ 65 
5.2.5 Oxidation of odd-numbered lipids ....................................................................................... 66 
5.2.6 Lipotoxicity ......................................................................................................................... 67 
5.3 Avocatin B induces autophagy ................................................................................................... 67 
5.4 Avocatin B as a novel therapy for AML .................................................................................... 69 
 viii 
 
5.5 Limitations .................................................................................................................................. 70 
5.6 Conclusions ................................................................................................................................ 71 
Appendix A: Research activity resulting from this program ................................................................ 72 
Bibliography ......................................................................................................................................... 73 
 
 ix 
 
List of Figures 
Chapter 1 
Figure 1.1. Schematic flow diagram of normal hematopoiesis and AML……………………………2 
Figure 1.2. Schematic diagram of fatty acid oxidation……………………………………………….6 
Figure 1.3. Intrinsic mitochondrial pathway of apoptosis…………………………….………………10 
Figure 1.4. Schematic illustration of autophagic vesicle generation…………………………………14 
Figure 1.5. Avocatin B’s chemical structure……………………………………………………….…16 
 
Chapter 4 
Figure 4.1. Avocatin B is selectively toxic toward AML cells………………………………….……32 
Figure 4.2. Avocatin B’s preferential toxicity is associated with CD33+/CD19- and CD34+/CD38- 
expression……………………….……………………………………………………………….……33 
Figure 4.3. Assessing avocatin B in enriched CD34 KG1A cells…………………………….....……34 
Figure 4.4. Avocatin B induces mitochondria-mediated apoptosis…….……………………….……36 
Figure 4.5. Avocatin B increases AIF protein expression……………………………………………37 
Figure 4.6. Assessing avocatin B’s impact on ΔΨm…………………………..……..………….……37 
Figure 4.7.  Schematic diagram of the fate of fatty acids in the cell…………….…...……….………38 
Figure 4.8. Avocatin B’s activity is dependent on the fatty acid metabolism pathway…………...…39 
Figure 4.9. Assessing avocatin B’s role in the fatty acid biosynthesis pathway…………….…..…...40 
Figure 4.10. Avocatin B’s activity is independent of the monounsaturated fatty acid biosynthesis 
pathway………………………………………………………………….……………………………41 
Figure 4.11. Avocatin B inhibits fatty acid oxidation resulting in reduced NADPH and elevated 
ROS…………………………………………………………………………………………………...44 
Figure 4.12. Avocatin B’s activity is independent of PPARα…………………………..……………45 
Figure 4.13. Mitochondria are functionally important for avocatin B-induced death………..…...…47 
Figure 4.14. CPT1 is functionally important for avocatin B induced death….…….……………..…48 
Figure 4.15. Avocatin B induces autophagy………………………………..………………………..50 
Figure 4.16. Autophagy is functionally important for avocatin B-induced death…………….….….52 
Figure 4.17. Bone marrow stromal co-culturing allows for the long term culture of primary cells.....53 
 x 
 
Table S4.1a. AML patient sample details used for annexin/PI…………………………………..…53 
Table S4.1b. AML patient sample details used for colony formation assays………………………54 
Supplementary figure 4.1. Avocatin B is the most active avocado lipid analogue. …………..……54 
Supplementary figure 4.2. Kinetics of avocatin B-induced death………..…….……………..….…55 
Supplementary figure 4.3. Cell cycle analysis of avocatin B treated TEX cells..………….……..…55 
Supplementary figure 4.4. Avocatin B increases ROS……………………..………………….……56 
Supplementary figure 4.5. Jurkat T cells cultured in ethidium bromide medium have reduced 
mitochondria……………………………………………………………………………………...…57 
Supplementary figure 4.6. Avocatin B’s cytotoxicity is dependent on [O2] …………….……...…57 
Supplementary figure 4.7. Avocatin B’s toxicity is dependent on basal levels of fatty acid 
oxidation……………………………………………………………………………...…….……..…58 
 
Chapter 5 
Figure 5.1. Avocatin B is sensitive towards leukemia cells…………………………………...……60 
 
 
 1 
 
Chapter 1: General Introduction 
1.1 Acute myeloid leukemia (AML) 
Acute myeloid leukemia (AML) is a devastating disease characterized by poor patient prognosis. 
Abysmal patient survival rates are due to high rates of disease relapse and failure to achieve remission 
due to two factors: 1) the treatment of AML is outdated, having been unchanged for the past 40 years [1-
3], and 2) the presence of leukemia stem cells (LSCs), which are responsible for drug resistance, as these 
are not targeted by current drugs, and disease propagation [4-6].  
 AML, a type of blood cancer, is a heterogeneous disease which results from the disruption of 
hematopoiesis resulting in hematopoietic insufficiency (Figure 1.1). The inadequate production of normal 
blood cells observed in AML is due to the uncontrolled proliferation and accumulation of immature 
myeloid cells, generally referred to as leukemic blasts, in the bone marrow [7]. AML is observed in 3-8 
per 100,000 people, with increasing incidence with age [8]. Approximately 12,000 people are diagnosed 
with AML in the United States annually, whereby 8,590 of them are predicted to die from the disease [9, 
10]. AML patients are faced with extremely poor prognosis, where patients 60 years or older have a 2-
year survival rate of less than 10% and median survival of less than 1 year. AML is the most common 
leukemia observed in adults, with a median patient age of 72 years old, and three quarters of patients with 
AML are 60 years of age or older [1, 9, 10]. Furthermore, AML accounts for 32% of cancer-related 
deaths in children [11]. 
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Figure 1.1. Schematic flow diagram of normal hematopoiesis and AML. In AML, myeloid stem cell 
differentiation is impaired resulting in the accumulation of immature myeloid cells. As a result, AML 
patients suffer from hematopoietic insufficiency due to lowered leukocyte and erythrocyte counts. 
Adapted from “Marieb, Elaine Nicpon,Hoehn, Katja. (2010) Human anatomy & physiology /San 
Francisco : Benjamin Cummings” using Servier Medical Art (Creative Commons Attribution 3.0 Unported 
License). 
1.1.1 Treatment 
AML therapy has essentially remained unchanged for the past 40 years. The first step in AML 
therapy, known as induction therapy, has relied on daunorubicin, an anthracycline, and the pyrimidine 
analog cytarabine as the backbone of chemotherapeutic treatment. This is known as the “3+7” treatment 
regimen, which consists of 3 days of daunorubicin (45-90mg/m
2
) followed by 7 days of intravenous 
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cytarabine (100-200 mg/m
2
) [1, 3, 11, 12]. Usage of daunorubicin and cytarabine in induction therapy 
causes remission in 65-75% of cases who are less than 60 years of age and 30-50% in patients older than 
60 years of age [1, 11, 13]. Induction therapy aims to achieve remission, which is characterized by the 
presence of less than 5% blasts in the bone marrow and to prevent the possibility of disease relapse. 
Treatment of older AML patients (e.g., >65) is complicated by increased resistance to therapy, 
and a higher incidence of co-morbidity and as these patients are less tolerant to the cytotoxicities of 
conventional chemotherapy [11, 13]. Daunorubicin and cytarabine are highly cytotoxic with side effects 
such as nausea, vomiting, pain, ataxia and haemorrhage. As such, only 30% of older AML patients 
receive treatment beyond supportive care [14]. This clearly warrants for the development of novel and 
safer AML treatment strategies. Current efforts have been made to improve complete remission rates 
whilst reducing cytotoxic side effects -such as increased dosing, the use of alternative anthracyclines (ie. 
Idarubicin), or the addition of other chemotherapeutic agents such as etoposide (topoisomerase II 
inhibitor), clofarabine, cladribine, and fludarabine (purine analogues). Unfortunately, no conclusive 
evidence has been generated to indicate that one treatment or new combinations should become the new 
chemotherapeutic standard [1, 9, 15]. 
1.2 Leukemia stem cells (LSCs) 
Leukemia is believed to be a hierarchical model similar to that of regular hematopoiesis with 
leukemia stem cells at the apex [16]. The first study supporting this involved the identification of a 
subpopulation of CD34+/CD38- AML cells that were capable of transplanting in an 
immunocompromised mouse, whereas the bulk population of cells were not [17]. Furthermore, serial 
transplantation of this cell subpopulation in mouse xenograft models displayed long-term engraftment as 
well as self-renewal properties [18]. This led to the belief that a subpopulation of LSCs is responsible for 
propagating and initiating disease. The discovery of LSCs that are responsible for the initiation and 
propagation of leukemia has great implications for the treatment of patients with this disease, as the 
discovery of LSC targeted therapies could dramatically improve overall patient survival rates [4]. 
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LSCs  comprise 0.1-1% of the blasts in AML and can be identified through morphological 
surface markers which differ from hematopoietic stem cells such as the absence of CD90 and the 
increased expression of CD34+/CD38- (which has shown initiation activity of leukemia), CD123 
(interleukin-3 receptor), CD45RA (naïve T cell marker), CD13 (myeloid antigen), CD44 (involved in 
cell-cell interactions and adhesion), CLL-1 (novel LSC antigen), CD96 (T cell receptor), TIM3 (T cell 
receptor), CD47 (involved in proliferation and adhesion), CD32 (B cell signal modulator), and CD25 
(interleukin-2 receptor) [4, 10, 19].  
Not only are LSCs implicated in disease propagation, they are also responsible for drug resistance 
resulting in eventual patient relapse. Unlike bulk AML blasts, LSCs possess adaptive properties that 
enable them to evade the cytotoxic effects of chemotherapeutics. Unlike bulk AML blasts, LSCs comprise 
0.1-1% of blasts and reside primarily in the bone marrow, which provides a protective niche from 
circulating chemotherapeutics [4, 10]. Furthermore, LSCs express the multidrug resistance efflux pump 
P-glycoprotein (ABCB1) that actively remove chemotherapeutics from the cell.  In addition, LSCs have 
been shown to reside mainly in the G0 cell cycle phase, implying that they are generally quiescent [4-6]. 
As current chemotherapeutics generally target fast cycling, proliferating cells, LSCs that are quiescent are 
generally unaffected. As such, future therapy must target LSCs to overcome drug resistance and disease 
relapse. 
1.3 Metabolic alterations in cancer cells 
In general, cancer cells have an altered metabolism allowing for the accumulation of metabolic 
intermediates that can be used as cellular building blocks to support increased cell division and thus 
conferring a growth advantage [20]. The most common alteration is the Warburg effect, a perturbation of 
glucose metabolism, where glycolysis is decoupled from pyruvate oxidation allowing for the collection of 
glucose-derived carbon molecules rather than oxidizing them to carbon dioxide [20].  
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Alteration of glutamine metabolism is often observed in cancer cells, where increased glutamine 
uptake is observed to generate reduced NADPH, which is integral for both lipid synthesis and the Krebs 
cycle [20, 21].   
Another type of metabolic alteration involves the oxidation of lipids and fatty acids (FAs). FAs 
are composed of a hydrocarbon chain with a terminal carboxyl group and are used as energy sources, 
membrane components and signaling molecules [20]. FAs originate from 2 sources: 1) exogenous sources 
or 2) from de novo FA synthesis. Normal human cells generally prefer exogenous sources of FAs, 
whereas tumor cells shift towards de novo FA synthesis [20]. 
The oxidation of fatty acids, also known as fatty acid oxidation (FAO), produces twice as much 
ATP compared to carbohydrates [21]. FAO takes place in mitochondria and peroxisomes, however; the 
mitochondria is the main site for FAO [22]. It consists of a cyclical series of reactions which shorten fatty 
acids (by 2 carbons), generating NADH, FADH2, and acetyl-CoA per cycle [21] (Figure 1.2). NADH and 
FADH2 enter the electron transport chain (ETC) to produce ATP whereas acetyl-CoA enters the Krebs 
cycle to generate ATP and further reducing equivalents for the ETC and other biological processes [21]. 
Chain shortening occurs via a cycle consisting of 4 enzymatic steps (Figure 1.2): (1) acyl-CoA 
dehydrogenase which dehydrogenates acyl-CoA fatty acid to 2-enoyl-CoA, (2) 2-enoyl-CoA hydratase 
which produces 3-hydroxyacyl-CoA, (3) 3-hydroxyacyl-CoA which is dehydrogenated by 3-hydroxyacyl-
CoA dehydrogenase to produce 3-ketoacyl-CoA and NADH, and (4) 3-ketoacyl-CoA thiolase which 
cleaves 3-ketoacyl-CoA to  produce a 2 carbon-shortened saturated acyl-CoA and an acetyl-CoA [22, 23].  
In order for FAs to undergo FAO, they must be transported into the mitochondria. Acyl-CoAs are 
incapable of crossing the mitochondrial membrane; therefore they must be transported by the carnitine 
shuttle. This is facilitated by carnitine palmitoyl transferase 1 (CPT1), which is found on the outer 
mitochondrial membrane and conjugates FAs with carnitine [21]. CPT1 is the rate limiting step of FAO 
as it exerts about 80% of control over the FAO pathway [23]. Once acyl-carnitines have entered the 
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mitochondria, CPT2, found on the inner mitochondrial membrane, reconverts the acyl-carnitines into 
usable acyl-CoAs to undergo FAO [22].  
 
 
 
Figure 1.2. Schematic diagram of fatty acid oxidation. Fatty acids are taken up into the mitochondria 
through CPT1 and CPT2 where they undergo a cyclical series of chain shortening reactions to generate 
NADH, acetyl-CoA and shortened acyl-CoA. Adapted from Houten et al. 2010 and Bartlett et al. 2004 
using Servier Medical Art (Creative Commons Attribution 3.0 Unported License). ACAD- acyl-CoA 
dehydrogenase; ECAH- 2-enoyl-CoA hydratase; HCAD- 3-hydroxyacyl-CoA dehydrogenase; KCAD- 3-
ketoacyl-CoA thiolase. 
FAO is essential for cell survival, whereby inhibition can lead to cell death through the 
accumulation of lipids (lipotoxicity) as well as deficiencies in metabolic intermediates [21, 24]. FAO is 
also implicated in the production of NADPH which allows for the recycling of reduced glutathione 
(GSH), which reduces oxidative stress through its antioxidant properties. Studies have demonstrated that 
ROS inhibits FAO and can be counteracted by antioxidants [25]. The reduction of NADP+ to NADPH is 
mediated by isocitrate dehydrogenases (IDHs) 1 and 2, which also catalyze the decarboxylation of 
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isocitrate to α-ketoglutarate [26]. IDH2 (found in the mitochondria) and IDH1 (found in the cytosol) play 
a key role in lipid biosynthesis, antioxidant systems and oxidative respiration. NADPH generated by 
IDHs are provided to fatty acid synthase for de novo synthesis of fatty acids [26] and help defend cells 
against oxidative stress caused by ROS generated from lipid oxidation [26]. As NADPH cannot pass 
through the inner mitochondrial membrane, NADPH generated by IDH2 serves as a primary source of 
antioxidants to combat mitochondrial specific ROS [26]. The role of IDHs in protecting against oxidative 
stress have been confirmed as IDH deficiency results in increased oxidative DNA damage, increased ROS 
from lipid peroxidation and increased peroxide generation [27].  
1.3.1 Metabolic alterations in leukemia cells 
Recently, mitochondrial alterations have been observed in leukemia cells. Such alterations 
include increased mitochondrial biogenesis [28] and mitochondrial uncoupling as a result of increased 
expression of uncoupling protein 2 (UCP2) [29, 30]. UCPs are mitochondrial anion carriers which 
dissipate the mitochondrial proton gradient resulting in a reduction in oxidative phosphorylation [21]. As 
such, mitochondrial uncoupling imparts a metabolic shift to the oxidation of other carbon sources, such as 
fatty acids and glutamine, to fuel the Krebs cycle [29, 31]. This is evident through increased lactate 
generation by leukemia cells despite aerobic conditions [31]. This is in stark contrast to normal coupled 
mitochondria which rely mainly on the oxidation of glucose-derived pyruvate as a primary carbon source. 
Uncoupled mitochondria display a reduced mitochondrial proton gradient (∆ψM) resulting in an inability 
to generate ATP, forcing cells to rely on glycolysis to meet energy demands [29].    
These metabolic alterations confer many advantageous benefits to leukemia cells. First, the use of 
non-glucose carbon sources acts as a safeguard for biosynthetic capacity. The oxidation of glucose via the 
Krebs cycle can result in shunting of anabolic pathways [31]. For example, pyruvate transamination can 
generate products which can block downstream processes such as NADPH and ribose-5-phosphate 
biosynthesis [31]. Next, depending on glycolysis over oxidative phosphorylation allows leukemia cells to 
thrive in reduced oxygen environments such as the hypoxic bone marrow niche [31]. Given the fact that 
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oxidative phosphorylation depends on adequate oxygen concentrations, this would not be sustainable in 
hypoxic environments. Next, mitochondrial uncoupling promotes resistance to mitochondrial intrinsic 
apoptosis through up regulation of Bcl-2 and antagonism of Bax/Bak proteins [24, 31].  Recently, LSCs 
have also been shown to display an overexpression in Bcl-2, where Bcl-2 favors apoptosis resistance, and 
also displays antioxidant properties through the reduction of ROS generation and facilitating the import of 
reduced glutathione into the mitochondria [31, 32]. Finally, reduced dependence on oxidative 
phosphorylation favors the generation of biosynthetic intermediates from the Krebs cycle [20, 31]. A shift 
towards fatty acid carbon sources over pyruvate results in the production of one less NADH and FADH2, 
whilst still yielding the same carbon intermediate products [31]. Notably, inhibition of FAO sensitized 
leukemia cells to chemotherapeutics, and promoted the pro-apoptotic proteins Bax/Bak [24].  
Given the numerous metabolic alterations in leukemia and LSCs, this presents novel 
chemotherapeutic targeting strategies for the eradication of AML.  
1.4 Leukemia cell death 
Cells can undergo programmed cell death through three distinct pathways – apoptosis, autophagy 
and necrosis. Autophagy, which constitutes the recycling of cellular components, generally functions as a 
survival mechanism; however, prolonged autophagic signaling can lead to cell death [33]. Apoptosis is a 
regulated process by which cells activate catabolic enzymes (i.e., caspases) resulting in cell death [34]. 
Necrosis, which constitutes the premature death of cells by autolysis, was once thought to be an 
unregulated form of cell death; however, recent studies have shown that it can be regulated [34].   
1.4.1 Apoptosis 
Apoptotic cell death is characterized by the shrinking of the cell and nucleus, plasma membrane 
blebbing, cleavage of cytoskeleton proteins, chromatin condensation, nuclear fragmentation and the 
formation of apoptotic bodies [34]. It can be induced by many stimulants such as DNA damage, cell 
starvation, ROS, death receptor ligand binding and/or other cellular stressors [34]. An early indicator for 
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apoptosis involves the externalization of phosphatidylserine (PS) to the outer leaflet of the plasma 
membrane. This acts as a signaling mechanism for phagocytes to target apoptotic cells for degradation 
[35].  
Apoptosis can occur via two different but convergent pathways: the death receptor (extrinsic) and 
the intrinsic mitochondrial pathways (Figure 1.3) [34, 36]. Caspase activation will determine which 
pathway a cell is to be inducted to. The death receptor pathway is activated by the binding of tumour 
necrosis factors (TNF) to cell surface death receptors. Binding of the factors to receptors leads to the 
formation of a death-inducing signaling complex. Aggregation of this complex then triggers an initiator of 
death receptor apoptosis, caspase 8 [36].  This initiates a caspase cascade by which executioner caspases 
3, 6, or 7 are activated. The executioner caspases in turn cleave proteins associated with structural and 
metabolic processes leading to apoptotic cell death [36]. The DNA repair enzyme poly-ADP-ribose 
polymerase (PARP) is cleaved by caspases 3 and 7 resulting in DNA fragmentation, a hallmark of 
apoptosis [34].  
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Figure 1.3. Intrinsic mitochondrial pathway of apoptosis. Apoptotic stimuli initiate permeabilization of 
the mitochondrial membrane pore resulting in the release of pro-apoptotic proteins. This leads to 
activation of caspases 9, 3, 6 and 7 resulting in apoptosis. Release of AIF and EndoG induce caspase-
independent apoptosis through direct DNA fragmentation. Adapted from Samudio et al. 2010 using 
Servier Medical Art (Creative Commons Attribution 3.0 Unported License). 
 
The mitochondrial, or intrinsic, apoptotic pathway occurs as a result of mitochondrial dysfunction 
and is controlled by members of the BCL2 family [34].  Initiation of this pathway involves changes in the 
permeability of the outer mitochondrial membrane as a result of changes to the mitochondrial membrane 
potential, allowing for the release of pro-apoptotic proteins such as cytochrome c, EndoG and apoptosis 
inducing factor (AIF) [36]. Caspase 9 acts as a central mediator of this pathway, which is initiated by 
cytochrome c, and is responsible for the formation of a multiprotein complex called the apoptosome [36].  
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Upon activation, the apoptosome mobilizes caspase 3, 6 and 7 which promote the cleavage of cellular 
proteins [34].  
Interestingly, apoptosis can also be induced independent of caspases. This is mediated by AIF and 
EndoG, which upon release from the mitochondria, translocates into the nucleus where it enacts large 
scale DNA fragmentation as well as chromatin condensation [36, 37]. AIF, is a flavoprotein which resides 
in the mitochondrial intermembrane space. Upon apoptosis induction and the permeabilization of the 
mitochondrial outer membrane, AIF is cleaved by cysteine proteases where is released into the cytosol to 
translocate into the nucleus [37].  AIF then interacts directly with DNA through its negatively charged 
surface, causing chromatin condensation and DNA fragmentation [38]. Activation of AIF induced cell 
death is strongly associated with exitotoxin drug treatment and growth factor deprivation [37, 39].  
1.4.2 Autophagy 
Autophagy constitutes the recycling of non-essential cellular components, damaged organelles or 
macromolecules and is a response mechanism to cellular stress that can arise from nutrient starvation, 
hypoxia, or drug treatment [33, 40-44]. Autophagy plays a role in tumour growth suppression, 
microorganism elimination and antigen presentation. Recycling of organelles or macromolecules is 
conducted by lysosomes in three different forms. In macroautophagy (generally referred to, and hereafter 
as autophagy) the double-membrane bound autophagosome, derived from the isolation membrane, 
envelops the material to be consumed and is then fused with a lysosome to form a single membrane 
bound unit called the autophagolysosome. In microautophagy, the lysosome engulfs the recyclable 
material via invagination of its membrane. In chaperone-mediated autophagy, cargo is delivered directly 
into the lysosomes by heat-shock proteins. Once delivered into the lysosome, acid hydrolases breakdown 
the ingested material into usable metabolic substrates. The formation of the autophagosome is closely 
regulated by a set of autophagy-related proteins (ATGs) [34].  
Most autophagy stimuli converge at the mammalian target of rapamycin (mTOR) and the class III 
phosphatidylinositol 3-kinase complex (PI3K), which serve as key autophagy regulators [42, 45]. The 
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core autophagy machinery required for autophagosome formation can be divided into four distinct 
groups: 1) ATG9 membrane protein, 2) unc-51-like kinase 1/2 (ULK1/2), 3) the PI3K complex, and 4) 
the microtubule-associated protein 1 light chain 3 alpha (LC3) and ATG12, a ubiquitin-like protein. 
Together, these proteins regulate the process of autophagy vesicle generation which can be divided into 
four steps: 1) initiation and nucleation, 2) elongation and closure, 3) maturation, and 4) degradation 
(Figure 1.4) [42, 44]. 
Initiation and nucleation. The beginning step to autophagy involves the formation of the isolation 
membrane. In starvation conditions, or another cell stressor conditions (such as oxidative stress), mTOR 
is inhibited resulting in dephosphorylation of ATG13. ATG13 then activates ULK1/2 via 
autophosphorylation resulting in the recruitment of focal adhesion kinase family interacting protein 
(FIP2000). The activated ULK-ATG-FIP2000 complex (mTORC) localizes to the developing isolation 
membrane to participate in elongation to promote a progression towards the complete autophagosome 
structure. In contrast, mTOR phosphorylates ATG13 preventing recruitment and activation of the ULK1/2 
complex during nutrient rich condition [42, 43]. Following initiation of the isolation membrane, 
nucleation arises when the PI3K complex binds to its core units such as Beclin 1 and p150. This complex 
resides on the isolation membrane and facilitates recruitment of other ATGs to the unit as well as 
produces phosphatidylinositol 3-phosphate, which is necessary for nucleation [8, 33, 42]. According to 
current consensus, the developing isolation membrane originates from the endoplasmic reticulum, the 
plasma membrane and the mitochondria [42]. 
Elongation and closure. The next step in autophagosome formation involves the development of 
the double-membrane-bound autophagosome from the precursor isolation membrane through the action 
of two ubiquitin-like conjugation systems: ATG12 and LC3 [8, 42, 43]. ATG12 is conjugated to ATG5 
by ATG7 and ATG10. Following, ATG16 conjugates to the complex and directs it to the phagophore. 
This complete complex is known as ATG16L (ATG12-ATG5-ATG16), and is essential for the formation 
of the autophagosome. ATG16L is also involved in aiding with the delivery of LC3 to the phagophore 
along with its lipidation [42]. The ubiquitin-like LC3 is a known marker of autophagy required for 
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generation of the autophagosome. LC3 undergoes post-translational c-terminal cleavage by the protease 
ATG4 to become its cytoplasmic form LC3-I. LC3-I is then conjugated with phosphatidylethanolamines 
(PE) to become LC3-II. This conjugation is mediated by ATG7, ATG3 and ATG16L. Upon lipidation, 
LC3-II can be inserted onto the surface of the autophagosomal membrane via its lipid moiety [33, 42-44].  
Maturation and degradation. This step involves the formation of the autophagolysosomes which 
consists of the fusion of autophagosomes to lysosomes. Unlike autophagosomes, autophagolysosomes are 
single-membrane bound vesicles which degrade the autophagosomes contents by acidic hydrolases and 
lysosomal proteases such as cathepsins. This fusion is mediated by RAB7 (RAS related protein), Beclin-1 
and LAMP-2 (lysosomal associated protein 2), however their mechanistic involvement remains to be well 
understood [42, 43]. Following degradation, broken down products are released into the cytosol as 
nutrients and pre-cursor building blocks [44]. 
Autophagy can be a highly selective process with adaptor molecules such as p62 (also known as 
sequestosome 1) which binds to ubiquinated targets, transports the targets to the lysosome, and binds to 
LC3-II to promote degradation [33, 43]. This highlights the importance of the ubiquitin-proteasome 
system in managing the selective targeting of autophagy. 
The role of autophagy in leukemia remains controversial as both the inhibition and activation of 
autophagy have been reported as promising treatment strategies [46]. Several reports suggest that 
activating autophagy leads to tumourigenesis by favoring atypical cell survival. Indeed, autophagy has 
been reported to promote tumour survival by restricting necrosis and inflammation and preventing cell 
death [47].  Additionally, autophagy-related gene (Atg)5 and Atg7 have been reported to promote cell 
survival [48] by allowing cancer cells to survive metabolic stress in response to nutrient deprivation. 
Further, in response to cell damage, autophagy can promote survival by removing damaged organelles. 
Given that many current chemotherapeutics induce metabolic stress and nutrient deprivation, the 
inhibition of autophagy is a promising strategy to increase treatment efficacy [49]. In contrast, there is 
strong evidence that autophagy induction acts as a tumor suppressor mechanism. Beclin 1, a regulator of 
autophagy responsible for autophagosome formation, has been linked to the stability and function of p53 
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[50], which is a crucial tumor suppressor protein that can initiate apoptosis [34]. Further, Atg12 promotes 
intrinsic apoptosis through inactivation of proteins of the anti-apoptotic Bcl-2 family [51].  In acute 
myeloid leukemia (AML), PI3K-Akt-mTOR, which is an essential signaling pathway for the activation of 
autophagy, is constitutively activated in 70-90% of patients and has been shown to contribute towards cell 
proliferation and drug resistance [52, 53].  Further, it has been experimentally demonstrated that 
rapamycin, a potent activator of autophagy, and rapamycin derivatives induce selective AML cell death 
[54, 55].   
 
Figure 1.4. Schematic illustration of autophagic vesicle generation. Formation of the autophagic vesicle 
consists of four steps: 1) Initiation and nucleation, 2) elongation and closure, 3) maturation, and 4) 
degradation. Initiation of the developing phagophore is dependent on the formation of the complex 
mTORC (ATG13-ULK1/2-FIP2000). Nucleation depends on the PI3K binding to its core partners Beclin 
1 and p150. Elongation and closure of the phagophore requires the formation of LC3-II through lipidation 
with phosphatidylethanolamine (PE). Maturation involves the fusion of the autophagosome and lysosome 
which is mediated by RAB2, Beclin 1 and LAMP2. Finally, degradation involves the lysing of cargo by 
cathepsins and subsequent release of broken down products. 
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1.5 Avocatin B 
To identify novel anti-cancer agents, our lab screened an 800 compound natural health products 
library to identify novel agents with anti-leukemia activity. Avocatin B (AVO), an avocado-derived lipid, 
was identified as the most potent compound at reducing leukemia cell viability. 
The avocado tree (Persea americana) originates from central America. Its fruit is highly 
consumed (1-2 per day) in various parts of Latin America without reports of any associated toxicity [56]. 
In fact, avocados are used in traditional herbal medicine for the treatment of various illnesses including 
hypertension, stomach ache, diarrhea and diabetes [57].  Avocado-derived phytochemicals also possess 
known chemopreventive characteristics [58]. These effects have been noted in malignant pleural 
mesothelioma, various carcinomas, various adenocarcinomas and oral cancer cell lines [58-60]. The 
chloroform extract (D003), prepared from the California Hass avocado, has displayed selective inhibition 
of pre- and malignant oral cancer cell lines [58]. D003 induced both death receptor and mitochondrial 
mediated apoptosis. D003’s activity was mediated by increases in ROS which were blocked using the 
anti-oxidant N-acetyl cysteine [58].  
Avocatin B, which consists of a 1:1 ratio of 1,2,4-trihydroxyheptadec-16-ene and 1,2,4-
trihydroxyheptadec-16-yne (Figure 1.5), is compound derived from the peel and seed of unripe avocado 
fruit which has been found to be cytotoxic towards a small panel of cancer cell lines [57, 61]. Activity has 
been reported in lung carcinoma, mammary adenocarcinoma, kidney carcinoma, pancreatic carcinoma 
with cytotoxicity in human prostate adenocarcinoma cells being nearly as potent as doxorubicin [57, 59]. 
Avocatin B has also been reported as a natural insecticide with potent activity in yellow fever mosquito 
larva, epimastigotes and trypomastigotes [57, 59].  
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Figure 1.5. Avocatin B’s chemical structure.  Avocatin B is an avocado derived compound consisting of 
1,2,4-trihydroxyheptadec-16-ene and 1,2,4-trihydroxyheptadec-16-yne (1:1 ratio). Image taken from 
ChemBankID:3198534. 
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Chapter 2: Objectives and Hypothesis 
The objectives of this project are:  
1. Characterize and evaluate avocatin B’s mechanism of action in acute myeloid leukemia cells in 
vitro and;  
2. Determine avocatin B’s efficacy in primary and primitive AML cells.  
 
These objectives fulfilled the hypothesis that:  
Avocatin B inhibits fatty acid oxidation to induce ROS-mediated autophagy and apoptosis in AML and 
LSCs.  
  
Short term goals:  
The short terms goals are to demonstrate avocatin B’s pre-clinical efficacy and determine 
avocatin B’s mechanism of action to further warrant investigation for the clinical application of treating 
acute myeloid leukemia.  
 
Long term goals:  
Upon successful completion of the aforementioned short term goals, the next steps would be to 1) 
determine pharmacokinetic properties and safety in animal models and 2) submit for Phase 1 clinical trial 
testing. 
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Chapter 3: Methods  
3.1 Methods 
3.1.1 Cell culture 
Leukemia (OCI-AML2,K562, HL60, KG1A; JURKAT, U937) cells were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM) (Life Technologies; Grand Island, NY) or RPMI Medium (Life 
Technologies) supplemented with 10% Fetal Bovine Serum (FBS; Seradigm; Providence, UT) and 
antibiotics (100 units/ml of streptomycin and 100 µg/m of penicillin; Sigma Chemical; St. Louis, MO).  
TEX leukemia cells were cultured in 15% FBS, antibiotics and 2mM L-glutamine (Sigma Chemical), 
20ng/ml stem cell factor and 2ng/ml IL-3 (Peprotech; Hamburg Germany). Lentiviral transduced ATG7, 
SQSTM1(p62), CPT1 (a gift from Dr. Aaron Schimmer, Toronto, ON) and PPARα OCI-AML2 
knockdown cell lines (a gift from Dr. Aaron Schimmer, Toronto, ON) were maintained in IMDM (Life 
Technologies) supplemented with 10% FBS (Seradigm) and 1ug/mL puromycin (Sigma-Alrich).  
Primary human samples (fresh and frozen) were obtained from the peripheral blood of AML 
patients who had at least 80% malignant cells among the mononuclear cells and cultured at 37°C in 
IMDM, 20% FBS and antibiotics (see supplementary table 1 for clinical parameters). Normal GCSF-
mobilized peripheral blood mononuclear cells (PBSCs) were obtained from volunteers donating 
peripheral blood stem cells for allotransplant and were cultured similar to the primary AML samples. The 
collection and use of human tissue for this study was approved by the local ethics review board 
(University Health Network, Toronto, ON, Canada; University of Waterloo, Waterloo, ON, Canada). All 
cells were maintained in a humidified atmosphere containing 5% CO2 at a temperature of 37°C. Cells 
were passaged every 3-4 days and passages 1-20 were used.  
3.1.1.1 Long-term culture 
Cells were cultured ex vivo using a mouse bone marrow stromal co-culturing system allowing for 
the long term expansion and culture (months instead of days) of primary CD34+ cells [62] using the 
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mural stromal cell line MS-5 and human cytokine supplementation. MS-5 cells were received as a gift 
from Dr. John Dick (Ontario Cancer Institute, Toronto, ON). Co-cultures were grown in H5100 media 
(StemCell Technologies) supplemented with 1% penicillin/streptomycin (Seradigm), GM-CSF 20ng/mL, 
IL3 10ng/mL, G-CSF 20ng/mL, TPO 50ng/mL, Flt3 10ng/mL, IL7 20ng/mL, SCF 100ng/mL, and IL6 
20ng/mL (Peprotech).  
MS-5 cells were grown on 0.1% gelatin (Sigma-Aldrich) coated 12 well plates. 48 hours later, 
primary cells were added and allowed to grow. Media was changed once a week and upon full confluency 
(~1 month), cells were trypsinized with 0.25% trypsin/0.1% EDTA (Sigma-Aldrich). Primary cells were 
then harvested and separated from MS-5 cells using a 40-micron cell strainer (BD Biosciences, 
Mississauga, ON.  
3.1.2 CD34+ cell enrichment 
TEX and KG1A cells were enriched for CD34+ population using the CD34+ EasySep Positive 
Selection Kit (StemCell) and EasySep Magnet (StemCell).  Approximately 2-5x10
8
 cells were re-
suspended in a 5mL polystyrene tube in 1mL of PBS (Sigma-Aldrich) containing 2% FBS (Seradigm) 
and 1mM EDTA (Sigma-Aldrich) (enrichment buffer). EasySep Positive Selection Cocktail was then 
added at 100 µL/mL cells and allowed to incubate at room temperature for 15 minutes. EasySep Magnetic 
Nanoparticles were then added at 50 µL/mL cells and allowed to incubate 10 minutes at room 
temperature. The tube was then placed inside the EasySep Magnet and left aside for 5 minutes. 
Following, the supernatant fraction was poured out resulting in the magnetically labeled cells to remain in 
the tube. Cells were then re-suspended in enrichment buffer and magnetic separation was repeated for a 
total of 5 times. The positively selected cells were then verified by flow cytometry. 
3.1.3 Flow cytometry 
Unless otherwise noted, all flow cytometry assays were performed in 96 well plates using a 
Guava easyCyte 8HT (Millipore, Billerica, MA) and GuavaSoft (Millipore) flow cytometry software. All 
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assays performed involved an unstained control to set basal thresholds as well as single stain controls (for 
multi-stain assays) to set compensation. 
3.1.3.1 Mitochondrial membrane potential assessment  
Following drug treatments, 0.5x10
6
 cells were collected and washed in 0.5mL PBS (Sigma-
Aldrich). 1µL of 30µM Rhodamine123 (R123; Enzo Life Sciences, Farmingdale, NY) was added to each 
sample and then allowed to incubate for 20 minutes in a humidified atmosphere containing 5% CO2 at a 
temperature of 37°C. Samples were then washed and measured using flow cytometry. R123 is a cationic 
dye is used to monitor the membrane potential of the mitochondria (Δψm) [63]. 
3.1.3.2 Mitochondrial integrity assessment  
0.5x10
6
 cells were collected from each cell line to be assessed and washed in 0.5mL PBS (Sigma-
Aldrich). 1µL of 50µg/mL nonyl-acridine orange (NAO) (Enzo Life Sciences) was added to each 
sample and then allowed to incubate for 20 minutes in a humidified atmosphere containing 5% CO2 
at a temperature of 37°C. Following, samples were washed and measured using flow cytometry. NAO is a 
mitochondria specific dye that binds to the mitochondrial phospholid cardiolipin and is taken up into the 
mitochondria independent of Δψ [64]. 
3.1.3.3 Cell surface marker assessment 
1x10
5
 cells were collected from each cell line tested. 2µL of fluorescently-conjugated cell surface 
receptor antibody was added to each sample and allowed to incubate for 30 minutes in the dark at room 
temperature. Cells were then washed twice in PBS (Sigma-Aldrich) containing 5% FBS (Seradigm) and 
then read using flow cytometry. Antibodies used include FITC mouse anti-human CD38 (BD 
Biosciences), PE mouse anti-human CD33 (BD Biosciences), APC mouse anti-human CD19 (BD 
Biosciences), APC mouse anti-human CD34 (BD Biosciences) and BD CompBeads anti-mouse Ig, k 
particles (BD Biosciences) as a positive control. 
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3.1.3.4 Reactive oxygen species detection 
Reactive oxygen species (ROS) were detected using 2′,7′dichlorohydrofluorescein-diacetate 
(DCFH-DA; Sigma Chemical) and dihyodroethidium (DHE; Sigma Chemical).  DCFH-DA is hydrolyzed 
by intracellular esterase to produce a non-fluorescent DCFH product. It can then be oxidized by ROS to 
produce a highly fluorescent DCF product [65]. DHE is a superoxide indicator which upon contact with 
superoxide anions produces the fluorescent product 2-hydroxyethidium [66]. Following drug treatment, 
TEX cells (5x105) were collected and washed in PBS (Sigma-Aldrich). Cells were stained with 5μM 
(final concentration) DCFH-DA or 10μM DHE and allowed to incubate for 30 minutes in a humidified 
atmosphere containing 5% CO2 at 37°C. Samples were then washed in PBS and ROS was measured by 
flow cytometry. 
3.1.4 Palmitate, malonyl-CoA, acetyl-CoA, and oleic acid study 
To assess avocatin B’s activity on fatty acid biosynthesis, TEX cells were co-incubated with the 
end-products of major enzymatic reactions of the fatty acid biosynthesis pathway, and assessed using 
MTS and annexin/PI viability assays. It was hypothesized that supplementation would rescue cells from 
avocatin B induced cell death. Palmitate, malonyl-CoA, acetyl-CoA and oleic acid (Sigma-Aldrich) were 
complexed to delipidized BSA (Sigma-Aldrich) based on the method by Luo et al. [67], where a 100mM 
stock was prepared in ethanol and then diluted to a working concentration in a 10%BSA-H2O solution.  
3.1.5 Western blotting 
3.1.5.1 Whole-cell lysate preparation 
Following drug treatments, cells were washed with ice-cold PBS, and then lysed with chilled 
RIPA buffer (Sigma-Aldrich) supplemented with protease inhibitors (Sigma-Aldrich) for 20 minutes. 
Next, cells were centrifuged at 13,200RPM for 20 minutes at 4°C and the supernatant was collected.  
 22 
 
3.1.5.2 Cell fractionation 
To separate cytosolic, mitochondrial and nuclear proteins, cell fractionation was performed using 
a protocol utilized by our collaborator Dr. Joe Quadrilatero (University of Waterloo, Department of 
Kinesiology). Following drug treatments, cells were washed with ice-cold PBS, and then lysed with 
chilled digitonin/sucrose buffer [250mM sucrose, 80mM KCl, and 50ug/mL digitonin] (Sigma-Aldrich). 
Next, the cytosolic fraction (supernatant) was collected through differential centrifugation at 16,000xg for 
10 minutes. The remaining fraction was then lysed with chilled muscle lysis buffer [20mM HEPES, 
10mM NaCl, 1.5mM MgCl, 1mM DTT, 20%, and 0.1% Triton X-100 at pH7.4] (Sigma-Aldrich). 
Following, the mitochondrial fraction (supernatant) was collected through differential centrifugation at 
1,000xg for 10 minutes. The nuclear fraction was retrieved by re-suspending the pellet in muscle lysis 
buffer and sonication for 2.5 second intervals for 20 seconds.  
3.1.5.3 BCA protein assay and sample preparation 
Total protein content was measured using the BCA protein assay. A standard curve was generated 
using bovine serum albumin (BSA) (Sigma-Aldrich) diluted in distilled water at concentrations ranging 
from 0mg/mL-1.0mg/mL. Diluted samples (tenfold) and standards were plated on a 96 well plate where 
200µL of bicinchoninic acid (BCA) working agent was added to each well (50 parts BCA:1 part copper 
II sulfate [Sigma-Aldrich]). The plate was then incubated for 30 minutes at 37°C. Optical density (OD) 
was then measured at 527nm using a spectrophotometer. Samples were prepared containing 30μg total 
protein, with ¼ sample buffer (240 mM Tris-HCl at pH 6.8, 6% w/v SDS, 30% v/v sucrose, 0.02% w/v 
bromophenol blue, and 50 mM DTT) volume and lysis buffer to a total volume of 30μl. Samples were 
heated at 95°C for 5 minutes and then loaded into polyacrylamide gel wells. 
3.1.5.4 SDS-PAGE  
Proteins were separated by SDS-PAGE in electrophoresis buffer (25 mM Tris base, 190 mM 
glycine, 3.5 mM sodium dodecyl sulfate) using a Mini Trans-Blot Cell (Bio-Rad, Hercules, CA), 
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followed by transfer of proteins onto a PVDF membrane (Bio-Rad) in transfer buffer (25 mM Tris base, 
190 mM glycine, 20% v/v methanol) using a Trans-Blot semi-dry transfer cell. Membranes were then 
blocked with 5% bovine serum albumin (BSA) in Tris-buffered saline (20 mM Tris base (TBS) plus 0.1% 
Tween (TBS-T) for 1 h at room temperature, followed by incubation with primary antibody added to 
blocking buffer overnight at 4°C. Membranes were washed three times with TBS-T, and then incubated 
with appropriate secondary antibody in blocking buffer for 1 h at room temperature. Membranes were 
washed five additional times with TBS-T. Western enhanced chemiluminescent substrate (ECL; GE 
healthcare; Baie d’Urfe, Quebec) was used to visualize proteins on a Kodak 4000MM Pro Imaging 
Station and Kodak Molecular Imaging software. 
3.1.5.5 Antibodies 
Antibody Isotype Molecular weight 
(kDa) 
Manufacturer 
AIF  mouse 57 Santa Cruz  
ANT1/2  goat 33 Santa Cruz  
Atg7 rabbit 78 Cell signaling  
Beclin-1 rabbit 60 Cell signaling  
Cytochrome c rabbit 14 Cell signaling  
ND1 goat 36 Santa Cruz  
Parkin mouse 50 Cell signaling  
PARP rabbit 89,116 Cell signaling  
SQSTM1/p62 rabbit 60 Cell signaling  
a-tubulin mouse 55 Santa Cruz  
LC3B rabbit 14,16 Cell signaling  
UCP2 Goat 70 Santa Cruz  
 
3.1.6 Cell growth and viability 
Cell growth and viability was measured using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium inner salt (MTS) reduction assay (Promega; 
Madison, WI) according to the manufacturer’s protocol and as previously described [68]. Cells were 
seeded in 96-well plates, treated with drug for 72 hours and optical density (OD) was measured at 490nm. 
Cell viability was also assessed by the trypan blue exclusion assay and by Annexin V and PI staining 
(Biovision; Mountainview, CA), as previously described [68].  Cell growth and viability under normoxic 
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(21% O2) and hypoxic conditions (1% O2) were measured using the sulforhodamine B assay, as 
previously described [69].  
3.1.7 Functional stem cell assays 
Clonogenic growth assays with primary AML and normal hematopoietic stem cells were 
performed, as previously described [68].  Briefly, CD34
+
 bone marrow-derived normal stem cells 
(StemCell Technologies; Vancouver, Canada) or AML mononuclear cells from patients with >80% blasts 
in their peripheral blood (4x10
5
 cells/ml) were treated with vehicle control or increasing concentrations of 
avocatin B and plated in duplicate by volume at 10
5
 cells/ml per 35 mm dish (Nunclon; Rochester, USA) 
in MethoCult GF H4434 medium (StemCell Technologies) containing 1% methylcellulose in IMDM, 
30% FBS, 1% bovine serum albumin, 3 U/ml recombinant human erythropoietin, 10
-4
 M 2-
mercaptoethanol (2ME), 2mM L-glutamine, 50ng/ml recombinant human stem cell factor, 10ng/ml 
recombinant human granulocyte macrophage-colony stimulating factor and 10ng/ml recombinant human 
IL-3. After 7-10 days of incubation at 37C with 5% CO2 and 95% humidity, the numbers of colonies 
were counted on an inverted microscope with a cluster of 10 or more cells counted as one colony. 
Mouse xenotransplant assays were performed as previously described [28, 70]. Briefly, AML 
patient cells were treated with 3.0µM avocatin B or dimethyl sulfoxide (DMSO) (as a control) for 48 
hours in vitro. Next, these cells were transplanted into femurs of sublethally irradiated, CD122 treated 
NOD/SCID mice and following a 6 week engraftment period, mice were sacrificed, femurs excised and 
bone marrow flushed and the presence of human myeloid cells (CD45
+
/CD33
+
/CD19
-
) were detected by 
flow cytometry. All animal studies were carried out according to the regulations of the Canadian Council 
on Animal Care and with the approval of the University Health Network, Animal Care Committee. 
3.1.8 High-throughput screen 
 A high throughput screen of a natural product library (n=800; Microsource Discovery Systems 
Inc.; Gaylordsville, CT) was performed as previously described [28, 68]. Briefly, TEX leukemia cells 
(1.5x10
4
/well) were seeded in 96-well polystyrene tissue culture plates.  After seeding, cells were treated 
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with aliquots (10µM final concentration) of the chemical library with a final DMSO concentration no 
greater than 0.05%. After 72 hours, cell proliferation and viability were measured by the MTS assay. 
3.1.9 Drug combination studies 
The combination index (CI) was used to evaluate the interaction between avocatin B and 
cytarabine.  TEX cells were treated with increasing concentrations of avocatin B in the presence and 
absence of cytarabine and after 72 hours cell viability was measured by the MTS assay. CI values, 
generated by the CalcuSyn median effect model, were used to evaluate whether the avocatin B/cytarabine 
combination was synergistic, antagonistic or additive.  CI values of <1 indicate synergism, CI=1 indicate 
additivity and CI>1 indicate antagonism [71, 72].  
3.1.10 mRNA detection 
Quantitative PCR were performed as previously described [73] in triplicate using an ABI 7900 
Sequence Detection System (Applied Biosystems) with 5 ng of RNA equivalent cDNA, SYBR Green 
PCR Master mix (Applied Biosystems, Foster City, CA, USA), and 400 nM of CPT1-specific primers 
(forward: 5’- TCGTCACCTCTTCTGCCTTT-3’, reverse: 5’-ACACACCATAGCCGTCATCA-3’,).  
Relative mRNA expression was determined using the ΔΔCT method as previously described [73]. 
3.1.11 Assessment of fatty acid oxidation and mitochondrial respiration 
Measurement of oxygen consumption rates were performed using a Seahorse XF24 extracellular 
flux analyzer (Seahorse Bioscience; North Billerica, MA). TEX cells were cultured in α-Minimum 
Essential Medium (Life Technologies) containing 1% FBS and plated at 1 x 10
5
 cells/well in poly-L-
Lysine (Sigma Chemical) coated XF24 plates. Cells were incubated with etomoxir (100µM; Sigma 
Chemical) or vehicle control for 30 minutes at 37°C in a humidified atmosphere containing 5% CO2.  
Next, palmitate (175µM; Seahorse Bioscience) or avocatin B (10µM) was added and immediately 
transferred to the XF24 analyzer. Oxidation of exogenous fatty acids was determined by measuring 
mitochondrial respiration through sequential injection of 5μM (final concentration) oligomycin, an ATP 
synthase inhibitor, (Millipore, Billerica, MA), 5μM CCCP, a hydrogen ion ionophore, (Sigma Chemical), 
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and 5μM rotenone (Millipore)/5μM antimycin A, which inhibit complex III activity, (Sigma Chemical). 
Fatty acid oxidation was determined by the change in oxygen consumption following oligomycin and 
CCCP treatment and prior to antimycin and rotenone treatment, according to the manufacturer’s protocol 
and as described in Abe et al. (2013) [74].  Data were analyzed with XF software (Seahorse Bioscience). 
3.1.12 NADPH detection 
 Nicotinamide adenine dinucleotide phosphate (NADPH) was measured by a commercially 
available Amplite™ Fluorimetric kit (AAT Bioquest; Sunnyvale, CA) according to the manufacturers’ 
protocol and as previously described [75], following incubation of increasing duration with avocatin B 
(10µM) or palmitate (175µM) in the presence or absence of etomoxir. Data are presented as a percent 
NADPH compared to control treated cells ± SD. 
3.1.13 Apoptosis measurements 
Apoptotic phenotype of Annexin V
+ 
(ANN)/Propidium Iodide (PI)
-
 was assessed using the 
ANN/PI assay, as previously described [76]. ANN binds to surface phosphatidylserine and PI transverses 
only disrupted plasma membranes to intercalate with DNA. Thus, measurements of ANN
+
/PI
-
 indicate 
apoptosis whereas ANN
+
/PI
+
, ANN
-
/PI
-
 indicate a dead or viable cell, respectively. Analysis of the sub 
G1 peak was performed by assessing cell cycle as previously described [68]. Briefly, TEX cells treated 
for 24 hours with 10µM avocatin B were harvested, washed with cold PBS and re-suspended in PBS and 
cold absolute ethanol. Cells were then treated at 37ºC for 30 min with 100 ng/mL of DNase-free RNase A 
(Invitrogen; Carlsbad, CA), washed with cold PBS, resuspended in PBS and incubated with 50 µg/mL of 
propidium iodine (PI) for 15 min at room temperature in the dark. DNA content was measured by flow 
cytometry and analyzed with the Guava Cell Cycle software (Millipore). Caspase activation was 
performed using a commercially available kit (Promega) and was performed according to the 
manufacturer’s protocol. Z-VAD-FMK (Sigma Chemical) was used as a pan-caspase inhibitor. Cleavage 
of poly (ADP) ribose polymerase (PARP), a DNA repair enzyme and a common downstream target of 
active caspase 3 and 7 were measured as previously described [76].  
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3.1.14 AIF and cytochrome c detection 
To determine avocatin B’s effect on the release of pro-apoptotic mitochondrial proteins 
cytochrome c and AIF, we used a flow cytometry-based assay as previously described [77, 78]. Briefly, 
pre-treated TEX cells (2 x10
5
) were collected and permeabilized in ice-cold digitonin buffer (50μg/ml, 
100mM KCl, in PBS) for 3-5 minutes on ice (until >95% cells were permeabilized, as assessed by trypan 
blue staining). Permeabilized cells were fixed in 4% paraformaldehyde (in PBS) for 20 minutes at room 
temperature, washed 3 times in PBS, and then resuspended in blocking buffer (0.05% saponin, 3% BSA 
in PBS) for 1 hour at room temperature. Cells were incubated overnight at 4°C with 1:200 cytochrome c 
antibody or AIF antibody (Santa Cruz Biotechnology) diluted in blocking buffer,  washed three times 
with PBS and then incubated for 1 hour at room temperature with 1:200 Alexa Fluor-488 donkey anti-
mouse IgG secondary antibody (Life Technologies) diluted in blocking buffer. Cells were washed three 
times in PBS and analyzed by flow cytometry using the BD FACS Calibur.  
3.1.15 Hypoxia experiments  
Cells were transferred to hypoxic culture chambers (MACS VA500 microaerophilic workstation, 
H35 HypoxyWorkStation; Don Whitley Scientific; UK) in which the atmosphere consisted of residual 
N2, 5% H2, 5% CO2 and 1% or 21% O2.  Cell growth and viability were measured by the sulforhodamine 
B assay (Sigma Chemical) following 72 hours of incubation. Data are presented as the % change in 
viability from 21%-1% oxygen.  
3.1.16 Autophagy detection 
Autophagy was detected by assessing lysosome size by confocal microscopy following cathepsin 
B staining, which increases in activity and intensity following autophagolysosome formation [79].  
Confocal microscopy of TEX cells was performed, as previously described [69]. Briefly, TEX cells (2.0 x 
10
5
) treated with avocatin B or vehicle control were incubated with Magic Red cathepsin B for 30 
minutes at 37
oC, according to manufacturer’s instructions (ImmunoChemistry Technologies, 
Bloomington, MN). Cells were then imaged on a Zeiss LSM 700 confocal microscope (Carl Zeiss, 
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Germany) using a 40x objective. Images were analyzed using LSM image analysis software (Carl Zeiss, 
Germany). Representative micrographs shown. 
3.1.17 RNAi knockdown of Atg7 and p62 
Lentiviral transductions were performed as described by Spagnuolo et al. 2013 [73]. Briefly, 
OCI-AML 2 cells (5 x 10
6
) were centrifuged and re-suspended in 6.5 mL media containing protamine 
sulfate (5 μg/mL) and 1 mL of virus cocktail (containing the short hairpin RNA (shRNA) sequence and a 
puromycin antibiotic resistance gene) and incubated overnight at 37
o
C. Following, the virus was removed 
from suspension by centrifugation and the cells were washed and resuspended in fresh media containing 
puromycin (1 μg/mL). After two days, puromycin resistant live cells were plated for viability and growth 
assays. The shRNA coding sequences were: Atg7 (Accession No. NM_006395.1-685s1c1): 5’- 
CCAAGGTCAAAGGACGAAGAT-3’, Atg7 (Accession No. NM_006395.1-1520s1c1): 5’-
GCTTTGGGATTTGACACATTT-3’, SQSTM1/p62 (Accession No. NM_003900.4-783s21c1): 5’-
GAGGATCCGAGTGTGAATTTC-3’, SQSTM1/p62 (Accession No. NM_003900.2-325s1c1): 5’-
CCGAATCTACATTAAAGAGAA-3’. These experiments were performed by Elena Kreinin. 
3.1.18 Interrogation of chemogenomics database 
The chemogenomic expression profiles of avocatin B and rapamycin were assessed in a publicly 
available yeast chemogenomics database (http://chemogenomics.pharmacy.ubc.ca/HIPHOP).  The 
database identified the top 15 yeast genes sensitive to drug treatment, based on fitness defect scores 
(p<0.05), and were assessed for gene ontology biological processes associated with autophagy and/or 
vesicle-mediated transport using AmiGO (Gene Ontology Consortium), as previously described [80, 81].  
3.1.19 Statistical analysis 
Statistical analysis was conducted using GraphPad Prism 5.0 (GraphPad Software, USA) using 
Student’s t-test for comparing two data sets, or one-way analysis of variance (ANOVA) with Tukey’s 
post hoc test for comparing three or more data sets. Unless otherwise noted, all results are presented as 
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mean ± SD. For graphs, *=p<0.05, **=p<0.01, and ***=p<0.001 compared to control cells. Drug 
combination data were analyzed using Calcusyn software (Biosoft; UK). 
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Chapter 4 Results 
*Note: Unless otherwise stated, data was generated by Eric A. Lee. 
4.1.1 A high-throughput screen for novel anti-AML compounds identifies avocatin B  
 To identify novel compounds with anti-AML activity we screened a commercially available 
natural health products specific library against TEX leukemia cells. These cells possess several LSC 
properties, such as marrow repopulation and self-renewal [28, 73, 82, 83]. The compound which imparted 
the greatest reduction in viability was avocatin B (Figure 4.1A; left panel, arrow indicates avocatin B).  
Avocatin B is a 1:1 mixture of two 17-carbon lipids derived from avocados and belongs to a family of 
structurally related lipids [84] (Figure 4.1A right panel, Avocatin B’s structure [85]). We tested 4 avocatin 
lipid analogues and determined that avocatin B was the most cytotoxic (EC50: 1.5 ± 0.75µM; 
supplementary figure 4.1).  
Avocatin B’s selectivity toward leukemia cells was validated in primary AML samples and in 
peripheral blood stem cells (PBSCs) isolated from GCSF-stimulated healthy donors. Avocatin B, at 
concentrations as high as 20µM, had no effect on the viability of normal PBSCs (n=4). In contrast, 
avocatin B reduced the viability of primary AML patient cells (n=6) with an EC50 of 3.9 ± 2.5 µM, 
which is similar to other recently identified compounds with anti-AML activity [28, 69, 70, 86] (Figure 
4.1B; see supplementary table 1 for patient sample characteristics).   
Avocatin B was also tested in combination with cytarabine; the primary backbone of current 
clinical AML therapy. The Calcusyn median effect model was used to evaluate whether the avocatin 
B/cytarabine combination was synergistic, antagonistic or additive [71, 72]. The cytarabine-avocatin B 
combination synergistically induced cell death in TEX cells with combination index values of 0.20, 0.19, 
and 0.15, at EC 30, 50 and 80, respectively (Figure 4.1C).  
4.1.2 Avocatin B is selectively toxic toward leukemia progenitor and stem cells  
 Given the selectivity toward AML patient samples over normal hematopoietic cells, we next 
assessed avocatin B’s effects on functionally defined subsets of primitive human AML and normal cell 
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populations.  Adding avocatin B (3µM) into the culture medium reduced clonogenic growth of AML 
patient cells (n=3; supplementary table 1 for patient characteristics). In contrast, there was no effect on 
normal cells (n=3; Figure 4.1D; left panel).   In addition, treatment of primary AML cells with avocatin B 
(3.0µM) reduced their ability to engraft in the marrow of immune deficient mice (Figure 4.1D; right 
panel).   Taken together, avocatin B selectively targets primitive leukemia cells.  
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Figure 4.1. Avocatin B is selectively toxic toward AML cells. (A) (Left panel) A screen of a natural 
health product library identified avocatin B as the most potent compound at reducing TEX leukemia cell 
viability. Cells were incubated with compounds for 72 hours and cell growth and viability were measured 
by the MTS assay. Arrow indicates avocatin B. Experiment was performed by Dr. Paul Spagnuolo. 
(Right panel) Avocatin B’s structure[85]. (B) Avocatin B’s activity was tested in peripheral blood stem 
cells (PBSCs; n=4) isolated from GCSF stimulated donors or cells isolated from AML patients (n=6). 
Primary cells were treated with increasing avocatin B concentrations for 72 hours and viability was 
measured by the Annexin V (ANN)/Propidium Iodide (PI) assay and flow cytometry. Data are presented 
as log10 EC50 values. Experiment was partially performed by Princess Margaret Cancer Centre. 
(C) Avocatin B was tested in combination with cytarabine using Calcusyn software as detailed in the 
methods section. Experiments were performed twice in triplicate; representative figure shown. (D) (Left 
panel) Primary AML (n=3) and normal (n=3) cells were cultured with avocatin B (3µM) for 7-14 days 
and clonogenic growth was assessed by enumerating colonies (colony defined as >10 cells). Data are 
presented as % clonogenic growth compared to control ± SEM, similar to previously described [28, 87]. 
Experiments were performed twice in triplicate. Experiment was performed by Sarah Rota. (Right 
panel) AML cells from one patient were treated with avocatin B (3µM) for 48 hours or a vehicle control 
and then intrafemorally injected into sublethally irradiated, CD122 treated, NOD/SCID mice 
(n=10/group). After 6 weeks, human AML cells (CD45
+
/CD19
-
/CD33
+
) in mouse bone marrow were 
detected by flow cytometry. Experiment performed by Princess Margaret Cancer Centre.**p<0.01; 
***p<0.001.    
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4.1.3 Avocatin B’s selective cytotoxicity correlates with CD33+/CD34+ expression 
In Section 4.1.1, Avocatin was tested in a number of leukemia cell lines (TEX, KG1A, OCI-
AML2, JURKAT). Avocatin B was also tested in additional leukemia cell lines (HL60, U937, and K562) 
where avocatin B did not display potent toxicity towards these lines (Figure 4.2 left panel). Next, we 
performed phenotypic assessment for CD33+/CD19- (myeloid marker) and CD34+/CD38- (stem cell 
marker) of our tested cell lines to identify a correlation with avocatin B’s activity. Here, we reported that 
TEX cells display both high proportions of CD33+/CD19- and CD34+/CD38- fractions whereas neither 
of the other AML lines displayed this phenotype (Figure 4.2 right panel). Next, we aimed to assess 
whether avocatin B was selectively toxic to CD34+ enriched cells. Therefore we enriched the KG1A cell 
line for CD34 positive cells (Figure 4.3A) and treated it with avocatin B (Figure 4.3B). These cells were 
still insensitive to avocatin B, suggesting that avocatin B’s preferential toxicity is associated with 
CD33+/CD19- and CD34+/CD38- expression.  
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Figure 4.2. Avocatin B’s preferential toxicity is associated with CD33+/CD19- and CD34+/CD38- 
expression. (Left panel)  Avocatin B was tested in a panel of leukemia cell lines (TEX, KG1A, AML2, 
HL60, U937, K562 and Jurkat) over 72 hours. Viability was measured by the MTS assay and data are 
presented as mean percentage of live cells. (Right panel)  The expression of cell surface markers for 
myeloid cells, CD33+/CD19-, and stem cells, CD34+/CD38-, was measured in our AML cell lines by 
flow cytometry.  All experiments were performed three times in triplicate, representative figures are 
shown. 
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Figure 4.3. Assessing avocatin B in enriched CD34 KG1A cells. (A)  KG1A cells were enriched for 
CD34 positive cells using the CD34+ EasySep Positive Selection Kit and EasySep Magnet. This was 
confirmed by flow cytometry. Representative dot plots are shown. (B)  Enriched CD34 KG1A cells were 
incubated with avocatin B over 72 hours. Viability was measured using the MTS viability assay and data 
are presented as mean percentage of live cells. All experiments were performed three times in triplicate, 
representative figures are shown. 
4.1.4 Avocatin B induces mitochondria-mediated apoptosis 
 We next assessed the mode of avocatin B induced leukemia cell death. Externalization of 
phosphatidylserine, an early marker of apoptosis detected by Annexin V, was observed in live cells (i.e., 
ANN
+
/PI
-
) treated with avocatin B and flow cytometry 48 hours post treatment (Figure 4.4A; 
F3,7=19.09;p<0.05; see supplementary figure 4.2 for raw data). This coincided with the occurrence of 
DNA fragmentation (Figure 4.4B; F4,14=171.4;p<0.001), caspase activation (Figure 4.4C; 
F3,16=69.56;p<0.001) and PARP cleavage (Figure 4.4D), as measured by cell cycle analysis (see 
supplementary figure 4.3 for raw data), a caspase activation assay and Western blotting, respectively.   
To test whether death was dependent on caspase enzymes we co-incubated avocatin B with the 
pan-caspase inhibitor Z-VAD-FMK or the caspase-3 specific inhibitor QVD for 72 hours. Both inhibitors 
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only slightly protected from avocatin B-induced death (F4,9=2.714;p<0.01; Figure 4.4E). Since cell death 
can occur independent of caspase enzymes through the release of mitochondria localized proteins such as 
apoptosis inducing factor (AIF), we tested for the presence of AIF in cytosolic fractions of avocatin B 
treated TEX cells. However, given that AIF release involves mitochondrial outer membrane permeability 
and that we detected caspase activation; we also simultaneously tested for the presence of cytochrome c, 
which activates caspase enzymes following its release from the mitochondrial intermembrane space. Cells 
treated with avocatin B showed an increase in cytoplasmic concentrations of AIF (F4,20=8.211;p<0.001; 
Figure 4.4F) and cytochrome c (F4,20=13.57;p<0.001; Figure 4.4F). To further support this, Western 
Blotting revealed an increase in AIF protein expression in avocatin B treated cells (Figure 4.5). 
Another characteristic associated with mitochondria-mediated apoptosis is the dissipation of the 
mitochondrial membrane potential (ΔΨm). Dissipation of ΔΨm has been associated with mitochondrial 
outer membrane permeabilization (MOMP) and the release of cytochrome c [88, 89]. It has also been 
reported that ΔΨm disruption can lead to ROS generation resulting in MOMP [88]. As such, we 
investigated whether avocatin B disrupted ΔΨm in TEX leukemia cells. Avocatin B treatment caused a 
significant reduction in ΔΨm consistent with the release of cytochrome c and AIF (Figure 4.6). Therefore, 
avocatin B induced apoptotic death characterized by the release of the mitochondrial proteins AIF and 
cytochrome c. 
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Figure 4.4. Avocatin B induces mitochondria-mediated apoptosis. (A) TEX cells were treated with 10µM 
avocatin B for increasing duration and phosphatidylserine exposure in live cells (i.e., apoptotic 
phenotype; ANN
+
/PI
-
) and (B) DNA fragmentation were measured by flow cytometry. Data are presented 
as fold change in apoptotic phenotype and percent cells in sub G1 peak, respectively. (C) TEX cells were 
treated with 10µM avocatin B for increasing duration and caspase 3 and 7 activation and (D) cleavage of 
PARP, a substrate of caspase 3, were measured by a commercially available activation assay and Western 
blotting, respectively. (E) TEX cells were treated with 10µM avocatin B in the presence and absence of 
the pan caspase inhibitor Z-VAD-FMK (ZVAD) or the caspase-3 specific inhibitor Q-VD-OPh (QVD). 
Viability was measured after a 72 hour incubation period by the MTS assay. Data are presented as percent 
change in viability compared to controls ± SD. (F) TEX cells were treated with 10µM avocatin B for 
increasing duration and cytochrome c and AIF release were measured in cytoplasmic fractions by flow 
cytometry.  Data are presented as percent of cells releasing cytochrome c or AIF ± SD. All experiments 
were performed three times in triplicate, representative figures are shown. *p<0.05; **p<0.01;*** 
p<0.001.    
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Figure 4.5. Avocatin B increases AIF protein expression. Western Blot of AIF (67kDa) protein in TEX 
cells treated with 10μM avocatin B or DMSO control over 24, 48 and 72 hours. Ponceau staining was 
used to quantify equal loading of samples.  
 
 
Figure 4.6. Assessing avocatin B’s impact on ΔΨm. (Left panel) TEX cells were incubated with 10μM 
avocatin B over a 48 hour time course. ΔΨm was assessed by rhodamine 123 staining and flow 
cytometry. Data are represented as %cells with disrupted ΔΨm. (Right panel) Histogram plot displaying 
shift in rhodamine 123 fluorescence after 36 hour incubation with avocatin B. ***p<0.001. 
 
4.1.5 Avocatin B’s activity involves the fatty acid metabolism pathway 
Prior to this study, little has been published on the mechanism of avocatin B with only reports of 
activity in various solid cancer cell lines [59]. However, similarly structured avocado-derived compounds 
have been shown to inhibit acetyl-CoA carboxylase, a key enzyme in fatty acid biosynthesis [90]. As 
such, we aimed to explore whether avocatin B also affected the fatty acid biosynthesis pathway (Figure 
4.7). We co-incubated TEX cells with avocatin B and palmitate, the end product of the fatty acid 
biosynthesis pathway, and reported that palmitate abrogated avocatin B’s cytotoxicity (Figure 4.8).  
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Figure 4.7.  Schematic diagram of the fate of fatty acids in the cell. Fatty acids can undergo fatty acid 
oxidation to fuel the Kreb’s cycle or can be converted to monounsaturated fatty acids to contribute 
towards the phospholipid bilayer. Adapted from Samudio et al. 2010 and Carracedo et al. 2013 using 
Servier Medical Art (Creative Commons Attribution 3.0 Unported License). 
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Figure 4.8. Avocatin B’s activity is dependent on the fatty acid metabolism pathway. (A)  TEX cells were 
co-incubated with 10µM avocatin B and increasing concentrations of palmitate over 72 hours. Viability 
was measured using the MTS viability assay and data are represented as mean percentage of live cells. 
(B) TEX cells were co-incubated with 50µM palmitate and increasing concentrations of avocatin B. 
Viability was measured using the ANN/PI flow cytometry assay and data are presented as mean 
percentage of live cells. All experiments were performed three times in triplicate, representative figures 
are shown. **p<0.01; ***p<0.001. 
 
Fatty acids, including palmitate, are produced by fatty acid synthase (FASN), a major enzyme 
involved in fatty acid biosynthesis, from the substrates acetyl-CoA, malonyl-CoA and NADPH [91, 92]. 
Given that palmitate rescued cells from avocatin B induced cell death, we investigated if avocatin B’s 
activity was dependent on FASN. We co-incubated TEX cells with avocatin B and orlistat, a chemical 
inhibitor of FASN (Figure 4.9A) [93]. Avocatin B’s activity was not affected by orlistat suggesting that 
its activity is not dependent on FASN.  
Upstream of FASN is acetyl-CoA carboxylase, an enzyme responsible for the production of the 
FASN substrate malonyl-CoA. Given that avocado-derived compounds with a similar structure to 
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avocatin B have been shown to inhibit acetyl-CoA carboxylase (ACC) [49], we investigated whether 
avocatin B’s activity was dependent on ACC. This was done by co-incubating avocatin B with acetyl-
CoA and/or malonyl-CoA (Figure 4.9B, C & D), which is produced by ACC. Unlike co-incubation with 
palmitate, acetyl-CoA and/or malonyl-CoA were not capable of affecting avocatin B’s activity in TEX 
cells indicating that ACC was not essential to its activity.  
 
Figure 4.9. Assessing avocatin B’s role in the fatty acid biosynthesis pathway. (A)  TEX cells were co-
incubated with 5µM avocatin B and increasing concentrations of the FASN inhibitor orlistat over 72 
hours. Viability was measured using the MTS viability assay and data are represented as mean percentage 
of live cells. (B) TEX cells were co-incubated with 10µM avocatin B and increasing concentrations of 
malonyl-CoA. Viability was measured using the MTS viability assay and data are represented as mean 
percentage of live cells. (C) TEX cells were co-incubated with 10µM avocatin B and increasing 
concentrations of acetyl-CoA. Viability was measured using the MTS viability assay and data are 
represented as mean percentage of live cells. (D) TEX cells were co-incubated with 10µM avocatin B and 
increasing concentrations of malonyl-CoA and acetyl-CoA. Viability was measured using the MTS 
viability assay and data are represented as mean percentage of live cells. All experiments were performed 
three times in triplicate, representative figures are shown.  
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Once fatty acids have been produced by FASN, they can be used as a metabolic fuel source 
through fatty acid oxidation, or they can be desaturated to monounsaturated fatty acids (MUFA) to 
contribute towards cellular tissues [94]. Stearoyl-CoA desaturase-1(SCD1) is an enzyme responsible for 
the conversion of saturated fatty acids to MUFAs. Oleic acid is the primary product from SCD1 [94]. To 
investigate whether avocatin B inhibited SCD1, we co-incubated avocatin B with oleic acid to see if could 
rescue cells from avocatin B’s cytotoxic effects (Figure 4.10).  Treatment with oleic acid failed to 
abrogate avocatin B’s activity indicating that its activity was unrelated to the MUFA pathway of fatty acid 
biosynthesis. Given that only palmitate rescued cells from avocatin B treatment, we chose to investigate 
downstream pathways such as fatty acid oxidation (next section). Thus, high palmitate concentrations 
rescue cells from death likely by outcompeting avocatin B for entry into mitochondria through CPT1. 
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Figure 4.10. Avocatin B’s activity is independent of the monounsaturated fatty acid biosynthesis 
pathway. (A)  TEX cells were co-incubated with 10µM avocatin B and increasing concentrations of oleic 
acid over 72 hours. Viability was measured using the MTS viability assay and data are represented as 
mean percentage of live cells. All experiments were performed three times in triplicate, representative 
figures are shown.  
4.1.6 Avocatin B inhibits fatty acid oxidation  
Apoptosis was characterized by the release of mitochondrial proteins following avocatin B 
treatment. Since avocatin B is a 17-carbon lipid and lipids of that size can enter the mitochondria and 
undergo fatty acid oxidation after they have been processed by carnitine palmitoyltransferase 1 (CPT1), 
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we evaluated the impact of avocatin B on fatty acid oxidation. Fatty acid oxidation produces acetyl-CoA 
which enters the TCA cycle to produce NADH, which fuels oxidative phosphorylation, and NADPH, an 
important co-factor that participates in catabolic processes during cell proliferation [95] and is the 
precursor of reduced glutathione - an important intracellular and mitochondrial antioxidant [96, 97] 
(Figure 4.11A). To test the effects of avocatin B on fatty acid oxidation, we measured mitochondrial 
bioenergetics of TEX cells pre-incubated with avocatin B or palmitate in the absence or presence of 
etomoxir by measuring the change in maximum oxygen consumption following oligomycin and CCCP 
treatment and prior to the addition of antimycin and rotenone, as described in Abe et al. (2013) [74]. As 
expected, treatment with palmitate increased the oxygen consumption rate (OCR), consistent with 
oxidation of exogenous fatty acid substrates and this increase was blocked by treatment with etomoxir, a 
CPT1 inhibitor (Figure 4.11B&C). Similarly, avocatin B reduced palmitate oxidation demonstrating that 
avocatin B inhibits the oxidation of exogenous fatty acids (F5,17=40.83;p<0.05; Figure 4.11B&C; arrows 
indicate the time when oligomycin, CCCP and antimycin/rotenone were added to the cells).  Future 
studies are needed to further determine the nature of CPT1’s preference for avocatin B over palmitate.   
4.1.7 Inhibiting fatty acid oxidation results in reduced NADPH and elevated ROS 
Inhibiting fatty acid oxidation can decrease NADPH and subsequently decrease antioxidant 
capabilities [75]. Thus, we tested the effect of avocatin B on NADPH levels in TEX leukemia cells. 
Avocatin B (10µM), similar to etomoxir (100µM), resulted in a 50% reduction in NADPH, an effect that 
was observed even in the presence of palmitate (175µM; F9,19=5.129;p<0.05; Figure 4.11D).   
Inhibition of fatty acid oxidation can reduce NADPH leading to reduced antioxidant capacity, 
elevated reactive oxygen species (ROS) and cell death [75]. ROS levels were tested in avocatin B treated 
cells using DCFH-DA and DHE, which measure general ROS and superoxide, respectively. TEX cells 
treated with avocatin B had a time-dependent increase in ROS levels as measured by DCFH-DA 
(F5,11=176.7;p<0.01; Figure 4.11E; see supplementary figure 4.4 for histogram data) and DHE 
(F5,11=36.75;p<0.01; Figure 4.11E; see supplementary figure 4.4 for histogram data). To test the 
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importance of ROS in avocatin B-induced death, we co-incubated cells with the antioxidants N-
acetylcysteine (NAC) or α-tocopherol (α-Toc). NAC neutralizes ROS through glutathione generation, 
which is reduced following NADPH depletion [75] and α-tocopherol is a lipid-based antioxidant that 
accumulates in organelle membranes, particularly mitochondria; to prevent lipid peroxyl radicals formed 
by ROS induced membrane damage [98]. Co-incubation with NAC (F3,7=70.55;p<0.05; Figure 4.11F, 
right panel) or α-tocopherol (F3,7=10.23;p<0.05; Figure 4.11F, right panel) abolished avocatin B-induced 
death. Daunorubicin (DNR) was used a negative control, as antioxidants do not protect against its 
cytotoxicity [99, 100]. Together, these results demonstrate that avocatin B reduces NADPH and that ROS 
is functionally important for avocatin B-induced death.  
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Figure 4.11. Avocatin B inhibits fatty acid oxidation resulting in reduced NADPH and elevated ROS. (A) 
Illustration of fatty acid oxidation in mitochondria. Long chain fatty acids (LCFA) enter the mitochondria 
via CPT1 for fatty acid oxidation to yield acetyl-CoA. Acetyl-CoA enters the TCA cycle to generate 
NADPH, an enzymatic co-factor and antioxidant. (ME: malic enzyme; IDH: isocitrate dehydrogenase; α-
KG: α-ketoglutarate).  (B) Oxidation of exogenous fatty acids was assessed by measuring the oxygen 
consumption rate (OCR) in TEX cells treated with palmitate (175µM), avocatin B (10µM), avocatin B 
and palmitate or palmitate and etomoxir (100µM). Arrows indicate the time when oligomycin, CCCP and 
antimycin/rotenone were added to the cells. Effects on fatty acid oxidation were measured with the 
Seahorse Bioanalyzer, as detailed in the methods section, and (C) quantified by peak area after 
oligomycin and CCCP treatment, as described by the manufacturer’s protocol and detailed in the 
methods. Data are presented as percent OCR compared to palmitate treated cells ± SD.  (D) NADPH was 
measured using the commercially available Amplite™ Fluorimetric Assay following treatment with 
avocatin B (10µM), palmitate (175µM) or etomoxir (100µM), according to the manufacturer’s protocol. 
Data are presented as a percent NADPH compared to vehicle control treated cells ± SD. (E) Reactive 
oxygen species (ROS) were measured in TEX cells treated with 10µM avocatin B for increasing time by 
DHE and DCFH-DA by flow cytometry. Data are presented as fold change in fluorescence, compared to 
vehicle control, ± SD from representative experiments. (F) TEX cells were treated with 10µM avocatin B 
in the presence or absence of the anti-oxidants, N-acetyl cysteine (NAC) or α-tocopherol (α-Toc). 
Daunorubicin (DNR) was used as a negative control.  Viability was measured by the ANN/PI assay and 
data are presented as mean percentage of viable cells (i.e., ANN
-
/PI
-
) ± SD from representative 
experiments. All experiments were performed three times in triplicate, representative figures are shown. 
*p<0.05; **p<0.01; ***p<0.001.    
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4.1.8 Assessing PPARα’s role in avocatin B mediated leukemia cell death 
Peroxisome proliferator-activated receptor (PPAR)α is a nuclear receptor protein that regulates 
FA oxidation and UCP expression, however its role in cancer cell proliferation remains unclear [20, 101, 
102]. In several cancer cell models however, activation of PPARα inhibited tumor growth [20]. To 
determine a possible role of PPARα, we tested avocatin B’s activity in PPARα knockdown cells. Cells 
lacking PPARα were equally sensitive to avocatin B as wild-type cells (Figure 4.12), suggesting that 
avocatin B’s effect on fatty acid oxidation is independent of PPARα. Although PPARα is central to FAO, 
PPAR transcription factors have multiple isoforms including PPAR delta and PPAR gamma. In fact, 
evidence suggests that a related family member PPAR delta is in fact required for the maintenance of 
HSCs and LSCs through FAO [21]. This result suggests that PPAR delta and PPAR gamma are related to 
avocatin B’s activity. Future studies should explore if PPAR delta and gamma play a role in regulating 
avocatin B’s activity.  
 
Figure 4.12. Avocatin B’s activity is independent of PPARα. (Left panel) mRNA expression 
demonstrating knockdown of PPARα in AML2 cells. Experiment performed by Princess Margaret 
Hospital. (Right panel) AML2 cells lacking PPARα   were co-incubated with increasing concentrations of 
avocatin B 72 hours. Viability was measured using the ANN/PI viability assay and data are represented as 
mean percentage of live cells. All experiments were performed three times in triplicate, representative 
figures are shown.  
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4.1.9 Mitochondria and CPT1 are functionally important for avocatin B-induced death 
We demonstrated that avocatin B inhibits fatty acid oxidation and induces apoptosis characterized 
by the release of mitochondrial proteins cytochrome c and AIF. Since avocatin B is a lipid and leukemia 
cells possess mitochondrial and metabolic alterations that increase their demand for fatty acid substrates 
[24], we hypothesized that avocatin B’s toxicity was related to its localization in mitochondria. To first 
test avocatin B’s reliance on mitochondria for cytotoxicity, we generated leukemia cells lacking 
functional mitochondria by culturing Jurkat-T cells in media supplemented with 50ng/ml of ethidium 
bromide (EtBr), 100mg/ml sodium pyruvate and 50µg/ml uridine, as previously described [103, 104].  
Following 60 days of passaging only live cells,  the presence of mitochondria were tested by flow 
cytometry following 10-nonyl acridine orange (NAO) staining and by Western blotting for mitochondrial 
specific proteins ND1 (i.e., complex 1) and adenine nucleotide translocator (ANT).  The significant 
reduction of mitochondria was confirmed, as cells co-cultured in EtBr containing media demonstrated a 
drastic reduction in NAO staining (supplementary figure 4.5) and a near absence of ND1 and ANT 
(Figure 4.13A). Avocatin B’s toxicity was abolished in cells lacking functional mitochondria, as 
measured by the ANN/PI assay (F2,12=6.509; p<0.001; Figure 4.13B).  Highlighting the utility of these 
cells in assessing mitochondrial participation in drug activity, we previously showed that cells lacking 
mitochondria were equally sensitive to their mitochondria containing controls when subjected to a 
compound that activates mitochondria-independent, calpain-mediated apoptosis [76].  
In hypoxic conditions (i.e., reducing oxygen concentrations), ATP production is shifted away 
from the mitochondrial pathways of oxidative phosphorylation and fatty acid oxidation toward glycolysis 
[105-107]. Thus, we compared avocatin B’s cytotoxicity in normoxic (21% oxygen) and hypoxic (1% 
oxygen) conditions. As controls, we tested drugs that directly target mitochondria such as antimycin and 
rotenone and drugs that do not directly target mitochondria such as cytarabine and daunorubicin. These 
controls demonstrated that the activity of mitochondria target drugs are reduced in hypoxic conditions 
whereas non-mitochondria target drugs are unaffected by these conditions. As expected, avocatin B’s 
activity was significantly reduced in conditions in which cellular metabolism is shifted away from 
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mitochondrial pathways (F4,24=98.51; p<0.0001; Figure 4.13C). However, it is important to note that 
although avocatin B’s activity was decreased in reduced oxygen; it did remain active at oxygen 
concentrations (i.e., 6.1% ± 1.7%[108]) found in bone marrow (supplementary figure 4.6). 
Excessive accumulation of fatty acids within the mitochondria increases the expression of 
uncoupling proteins (UCP) [109].  Thus, we measured expression of UCP2, the leukemia specific UCP 
[30], as an indirect measure of mitochondrial fatty acid accumulation by Western blotting. Treatment with 
avocatin B increased UCP2 protein expression in leukemia cells (Figure 4.13D).  
Figure 4.13. Mitochondria are functionally important for avocatin B-induced death. (A) Jurkat T cells 
were cultured in 50ng/ml of ethidium bromide, 100mg/ml sodium pyruvate and 50µg/ml uridine for 60 
days to create Jurkat-EtBr cells which lack functional mitochondrial. To confirm that Jukat-EtBr cells 
lack mitochondria, we measured the mitochondria specific markers adenine nucleotide translocator 
(ANT) and complex I (ND1) by Western blotting. (B) Avocatin B’s activity was tested in cells with 
(JURK) and with reduced (JURK-EtBr) mitochondria. Viability was measured by the ANN/PI assay and 
flow cytometry and data are presented as mean percentage of live cells (i.e., ANN
-
/PI
-
) ± SD from 
representative experiments. (C) TEX cells were grown in normoxic (21%O2) or hypoxic (1%O2) 
conditions and treated with avocatin B (2µM), antimycin A (1µM), rotenone (3µM), daunorubicin (5nM) 
or cytarabine (4nM). Cell viability was measured by the sulforhodamine B assay, as described in the 
methods, following a 72 hour incubation period. Data are presented as percent viable. Experiment 
performed by Princess Margaret Cancer Centre. (D) Uncoupling protein 2 (UCP2) was measured in 
whole cell lysates of avocatin B (10µM) or DMSO-control treated TEX cells by Western blotting. 
Arbitrary units (AU) are presented as fold change (compared to the 6 hour time point) and were 
calculated by dividing each treatment lane by the densitometry of its loading control. Densitometry was 
calculated as outlined in the methods. All experiments were performed three times in triplicate, 
representative figures are shown. *p<0.05; **p<0.01***; p<0.001. 
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Lipids of 16-20 carbon length enter mitochondria by the activity of CPT1 [110]. To determine the 
role of CPT1 in avocatin B-induced death we blocked CPT1 activity chemically with etomoxir and 
genetically using RNA interference. Etomoxir concentrations that did not reduce viability (100µM; 
F3,11=19.81;p<0.001; Figure 4.14A), abrogated avocatin B-induced cell death (F5,17=94.45;p<0.001; 
Figure 4.14B). As a genetic approach, we generated cells with reduced CPT1A gene expression (Figure 
4.14C, left panel). CPT1A knockdown cells were significantly less sensitive to avocatin B 
(F9,32=23.73;p<0.001; Figure 4.14C, right panel). Together, these results suggest that avocatin B is a lipid 
that localizes to the mitochondria and impairs fatty acid oxidation.  
 
Figure 4.14. CPT1 is functionally important for avocatin B induced death. (A) TEX cells were incubated 
with increasing concentrations of the CPT1 inhibitor etomoxir for 72 hours.  (B) Avocatin B’s (10µM) 
activity was tested in the presence of etomoxir (100µM; which does not impart toxicity) or (C) (right 
panel) in cells lacking CPT1A. (left panel) mRNA expression demonstrating knockdown of CPT1A. 
Experiment performed by Princess Margaret Cancer Centre.. Unless otherwise noted, viability was 
measured by the ANN/PI assay and flow cytometry and data are presented as mean percentage of live 
cells (i.e., ANN
-
/PI
-
) ± SD from representative experiments. All experiments were performed three times 
in triplicate, representative figures are shown. *p<0.05; **p<0.01***; p<0.001.    
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4.1.10 Avocatin B activates autophagy 
Treatment with avocatin B resulted in a delayed onset of death (i.e., after 24-48h), which was 
ROS-dependent (ROS increased after 18h of incubation) [111]. ROS-induced cell death can occur via 
apoptosis (type I programmed cell death) or autophagy (type II programmed cell death). Autophagy is 
classically activated by nutrient starvation [112] and autophagic cell death can occur following prolonged 
autophagic signaling [113]. Given the delayed onset of death that was characterized by increased levels of 
ROS [111] and that death follows inhibiting leukemia cells of an essential metabolic substrate (i.e., fatty 
acids), we assessed whether avocatin B activated autophagy. 
First, we interrogated databases derived from haploinsufficiency profiling (HIP) in yeast, a 
validated chemical genomics platform used to identify cellular response patterns [28, 80, 114, 115]. 
Briefly, HIP in Saccharomyces cerevisiae allows for the quantitative measurement of the relative drug 
sensitivity of 6000 yeast genes [115]. Avocatin B was tested in a yeast chemogenomic screen consisting 
of >3250 small molecules [116] and its chemogenomic profile was retrieved from the HIPHOP yeast 
chemogenomics database and interrogated for mechanistic sensitivities. Of the top 15 genes sensitive to 
avocatin B (p<0.05), 4 have known biological associations with autophagy and/or vesicle-mediated 
transport (Figure 4.15A). Notably, 3 out of the 4 identified genes belong to the SEC protein family, which 
are essential for autophagosome formation [117, 118]. We also compared avocatin B’s chemogenomic 
profile to rapamycin, a known autophagy inducer in mammalian cells. Similarly, 3 out of the top 15 genes 
sensitive to rapamycin have known biological associations with autophagy and/or vesicle-mediated 
transport (Figure 4.15A). Together, these findings suggest autophagy is mechanistically involved in 
avocatin B’s activity.  
 To assess whether avocatin B activates autophagy in leukemia cells, we examined changes in 
lysosome size following cathepsin B staining by confocal microscopy. Lysosome size was increased in 
avocatin B treated TEX cells consistent with the creation of autophagolysosomes (Figure 4.15B) [79, 
119]. A panel of autophagy markers was also tested by immunoblotting. Consistent with an autophagy 
response, avocatin B increased protein levels of Atg7, critical in autophagosome formation [42], and 
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mediated the conversion of LC3I to LC3II, a gold standard autophagy marker involved in autophagosome 
formation [42]. Moreover, avocatin B decreased protein levels of p62, an adaptor molecule that facilitates 
the interaction between ubiquitinated targets and LC3II [33] and Nix/BNIP3, a mitochondrial specific 
protein that is ubiquitinated prior to mitochondrial degradation [33, 120] (Figure 4.15C). Taken together, 
avocatin B activates autophagy in leukemia cells.  
 
 
Figure 4.15. Avocatin B induces autophagy. (A) Interrogation of avocatin B’s chemogenomic profile 
from a publicly available yeast chemogenomics database. (Left panel) Identification of genes related to 
autophagy and/or vesicle-mediated transport that are sensitive to avocatin B or rapamycin treatment. 
(Right panel) List of genes found in top 15 HET fitness scores related to autophagy and/or vesicle-
mediated transport that sensitive yeast to avocatin B or rapamycin treatment. (B) Avocatin B increases 
lysosome size as measured by confocal microscopy. Following a 24 and 48 hour incubation period with 
1.5μM avocatin B, TEX leukemia cells were stained with cathepsin B, a lysosomal protease, and 
lysosomes were observed by confocal microscopy. At 24 and 48 hours, the presence of larger vesicles is 
consistent with the formation of autophagolysosomes (representative figures shown). Experiment was 
performed by Dr. Paul Spagnuolo. (C) Avocatin B (1.5μM) increases protein levels of Atg7 and 
LC3B-II, and decreases protein levels of p62 and BNIP3L in TEX leukemia cells treated for 24 and 48 
hours. Proteins were measured by Western blotting and α-tubulin was used as a loading control. 
Experiment was partially performed by Elliott McMillan.  
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4.1.11 Autophagy is functionally important for avocatin B-induced death 
 We previously demonstrated that avocatin B induces selective leukemia cell death following the 
release of mitochondrial pro-apoptotic proteins cytochrome c and AIF [111]. Next, we aimed to evaluate 
whether autophagy was critical to avocatin B’s cytotoxicity. Thus, we generated Atg7 and SQSTM1/p62 
knockdown cell lines (Figures 4.16A &B). Consistent with previous reports demonstrating the importance 
of Atg7 in autophagy induction [121], Atg7 knockdown cells were significantly less sensitive to avocatin 
B (F6,24=53.07;p<0.001; Figure 4.16A, right panel). In contract, but similar to reports highlighting that 
genetic knockdown of SQSTM1/p62 increased autophagy signaling [122] and ROS levels leading to 
reduced viability of Ras transformed lung cancer cells [123],   knockdown of SQSTM1/p62 renders 
leukemia cells more sensitive to avocatin B (Figure 4.16B, right panel).  Indeed, basal ROS levels were 
elevated in SQSTM1/p62 knockdown cells compared to GFP controls (Figure 4.16C).  Collectively, these 
results suggest that autophagy is functionally important in avocatin B-induced death. 
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Figure 4.16. Autophagy is functionally important for avocatin B-induced death. (A) (Left panel) 
Immunoblots and densitometry showing protein levels of Atg7 in OCI-AML2 cells treated with scramble 
or 2 independent Atg7 vectors. Arbitrary units were normalized to loading controls (GAPDH) and 
standardization to GFP controls. Experiment was performed by Leonard Angka. (Right panel) 
Avocatin B was tested in cells lacking Atg7. Viability was measured by the ANN/PI assay and flow 
cytometry and data are presented as mean percentage of live cells (i.e., ANN
-
/PI
-
) ± SD from 
representative experiments.  (B) (Left panel) Immunoblots and densitometry showing protein levels of 
p62 in OCI-AML2 cells treated with GFP or 2 independent p62 vectors. Arbitrary units were calculated 
as above. Both bands of p62 were quantified, the top band represents the UBA-conjugated p62 protein. 
Experiment was performed by Leonard Angka. (Right panel) Avocatin B was tested in cells lacking 
SQSTM1 (p62). Viability was measured by the ANN/PI assay and flow cytometry and data are presented 
as mean percentage of live cells (i.e., ANN
-
/PI
-
) ± SD from representative experiments. (C) Basal ROS 
levels were detected in GFP and SQSTM1 knockdown cells using DCF-DA and DHE, as outlined in the 
methods. All experiments were performed three times in triplicate, representative figures are shown. 
*p<0.05; **p<0.01***; p<0.001.    
4.1.12 Establishing a methodology for the long-term culture of primary AML samples 
In our studies, we assessed avocatin B`s anti-leukemia activity in primary AML and normal 
CD34+ hematopoietic cells. In order to facilitate the long-term use of these cells, we used a mouse bone 
marrow stromal co-culturing system (Chapter 3: Methods) allowing for the long term expansion and 
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culture of primary AML and CD34+ normal cells [62]. Through co-culturing with stromal cells, we were 
able to create a simulated bone marrow microenvironment, which is essential in preventing cell 
differentiation and preventing apoptosis through the up regulation of anti-apoptotic proteins [124]. Using 
this co-culturing system, we were able to expand and grow primary cells for an extended period of time 
(Figure 4.17).  
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Figure 4.17. Bone marrow stromal co-culuring allows for the long term culture of primary cells. Cell 
counts of normal CD34+ hematopoietic cells co-cultured with mouse bone marrow stromal cells over a 
period of 25 days. Cells were counted using the trypan blue exclusion assay and a hemocytometer.  
 
 
 
4.2 Supplemental figures 
Table S4.1a. AML patient sample details used for annexin/PI 
 
Label # 
CD34 
(%) 
Interpretation 
AML1 77 
43~44,XX,dic(3;12)(p13;p11.2),-5,-7,+del(11)(q13),?dup(18)(q21q22),del(20)(q13.1), 
-22,+mar[cp10] 
AML2 88 44~48,XX,del(5)(q13q33),i(9)(p10),-18,add(20)(q13.3),+mar[cp17]/46,XX[3] 
AML3 87 46,XX,t(2;8)(p13;q22)[20].ish t(2;8)(MYC+;MYC-) 
AML4 1 NPM, Flt3-TKD 
AML5 60 ** 
AML5 77 Del 5q 
** Denotes unknown/not tested 
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Table S4.1b. AML patient sample details used for colony formation assays 
Label # 
CD34 
(%) 
Interpretation 
AML6 
** 
43,XY,del(5)(q13q33),-7,t(9;12)(q12;q12),der(16)t(16;17)(q12.1;q21), -17,-
18[4]/44,idem,+8[2]/46,XY[3] 
AML7 ** 46,XX,t(9;11)(p22;q23)[20] 
AML8 ** 46,XY,del(5)(q22q31)[20] 
** Denotes unknown/not tested 
 
 
 
Supplementary figure 4.1. Avocatin B is the most active avocado lipid analogue. (A) TEX cells were 
treated with increasing concentrations of avocado lipid analogues. Avocatin B imparted the greatest 
reducing in TEX cell viability. Data are presented as mean percentage of live cells (MTS assay) ± SD 
from representative experiments.  Experiments were performed three times in triplicate.  
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Supplementary figure 4.2. Kinetics of avocatin B-induced death.  TEX cells were treated with 10µM 
avocatin B and (A) apoptotic cells (ANN+/PI-) and (B) cell viability (ANN-/PI-) were measured by flow 
cytometry. Data are presented as mean percentage of apoptotic or live cells ± SD. All experiments were 
performed three times in triplicate.  
 
 
Supplementary figure 4.3. Cell cycle analysis of avocatin B treated TEX cells. TEX cells were 
incubated with avocatin B (10µM) over a 48 hour time course and cell cycle analysis was performed by 
propidium iodide staining and flow cytometry. Data are presented as percentage of cells per cell cycle 
phase ± SD from representative experiments. All experiments were performed three times in triplicate. 
***; p<0.001.    
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Supplementary figure 4.4. Avocatin B increases ROS. TEX cells were treated with 10µM avocatin B 
and DCFH-DA and DHE were measured at increasing time points by flow cytometry. Raw data showing 
the homogenous cell shift in DCFH-DA or DHE are shown.   
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Supplementary figure 4.5. Jurkat T cells cultured in ethidium bromide medium have reduced 
mitochondria. (A) Jurkat T cells were cultured in ethidium bromide media for 60 days and mitochondria 
were detected by nonyl acridine orange (NAO) staining, which binds to the mitochondria specific lipid, 
cardiolipin. (Left panel) Jurkat T cells demonstrate positive NAO staining whereas (right panel) Jurkat-
EtBr cells demonstrate a drastic reduction in NAO staining (~87%). 
 
 
 
Supplementary figure 4.6. Avocatin B’s cytotoxicity is dependent on [O2]. (A) TEX cells were grown in 
normoxic (21%O2) or hypoxic (3% and 1%O2) conditions and incubated with avocatin B (2µM) for 72 
hours. Cell viability was measured by the sulforhodamine B assay, as described in the methods. Data are 
presented as mean percentage of live cells ± SD. All experiments were performed three times in triplicate. 
***; p<0.001. Experiment performed by Princess Margaret Cancer Centre.   
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Supplementary figure 4.7. Avocatin B’s toxicity is dependent on basal levels of fatty acid oxidation. 
Basal levels of fatty acid oxidation were tested in TEX (avocatin B sensitive) and KG1a (avocatin B 
insensitive) cells were treated, as described in the methods sections.  
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Chapter 5: Discussion 
 A screen of a natural health product library identified avocatin B as a novel anti-AML agent. In 
vitro and pre-clinical functional studies demonstrated that it induced selective toxicity toward leukemia 
and leukemia stem cells with no toxicity toward normal cells. Mechanistically, we highlight a novel 
strategy to induce selective leukemia cell death where mitochondrial localization of avocatin B inhibits 
fatty acid oxidation leading to reduced levels of NADPH and ROS-dependent, caspase and AIF-mediated 
apoptosis.   
5.1 Avocatin B’s selectivity 
Avocatin B targets leukemia over normal cells. We propose this specificity is related to the 
leukemia cell’s altered mitochondrial characteristics, as a number of observations suggest avocatin B 
localizes in mitochondria. For example, (1) cells with significantly reduced mitochondria or (2) lacking 
the enzyme that facilitates mitochondrial lipid transport, CPT1, are insensitive to avocatin B; (3) chemical 
treatment with etomoxir, a CPT1 inhibitor, blocked avocatin B’s activity; (4) CPT1 only facilitates entry 
of lipids of avocatin B’s size into mitochondria (e.g., 16-20 carbons [110]; avocatin B:17 carbons [85]); 
and (5) UCP2 levels are increased following avocatin B treatment.  Leukemia cells contain higher 
mitochondrial mass [28] and greater demand for fatty acid substrates for metabolic activity [24] compared 
to normal hematopoietic cells [24]. Thus, given the leukemia cell’s mitochondrial phenotype, we propose 
that avocatin B accumulates with greater concentration in leukemia over normal cells, thus conferring its 
increased toxicity toward leukemia cells. 
In both normal CD34+ hematopoietic cells and peripheral blood stem cells, we reported that 
avocatin B imparted no toxicities at concentrations as high as 20µM whereas in primary AML cells, 
avocatin B had an EC50: 3.9 ± 2.5µM (chapter 4). These results suggest indeed that avocatin B’s 
selectivity resides in these differences between AML and normal hematopoietic cells.  
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To confirm avocatin B’s selectivity towards AML cells, Dr. Spagnuolo conducted a preliminary 
screen of avocatin B in other cell lines consisting of both cancer and normal models (Figure 5.1).  Here, it 
was reported that avocatin B only reduced the viability of leukemia cells tested, whilst normal cells, 
including kidney and lung, and other cancers, including myeloma and solid tumours, were unaffected by 
avocatin B treatment. This serves as a preliminary indicator that used as a chemotherapeutic, avocatin B 
will not impart toxicities into other body tissues.  
 
Figure 5.1. Avocatin B is sensitive towards leukemia cells. Various cancer and normal cell lines were 
incubated with increasing dose of avocatin B and incubated over 72 hours. Viability was assessed using 
the MTS assay and data are represented as mean percentage of live cells. This work was performed by Dr. 
Paul Spagnuolo at the Princess Margaret Cancer Hospital (Toronto, ON). Cell lines: HEK293 human 
embryonic kidney; MRC-7  human foetal lung; HT-1080  fibrosarcoma/connective tissue; Lp1 myeloma; 
4921 myeloma; Hela cervical cancer; HCT-116 colon carcinoma; MDA-468 Breast cancer; U937 
leukemia; TEX leukemia. 
 
In chapter 4, we established that avocatin B’s mechanism of action involves the inhibition of fatty 
acid oxidation. This is mechanism takes advantage of the altered metabolic preference for fatty acids 
present in leukemia cells over hematopoietic cells. Of concern however, is that fatty acid oxidation is 
important for energy homeostasis in cardiac muscles, skeletal muscles, liver and to some degree kidney, 
small intestines and adipose tissue [22, 23]. Patients with fatty acid oxidation defects have been  reported 
with hypoketonic hypoglycemia, cardiomyopathy and/or rhabdomyolysis [23].  As such, future animal 
studies should carefully monitor for any associated toxicities. 
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In chapter 4, we report that avocatin B inhibits fatty acid oxidation in leukemia cells at a 10-fold 
less concentration than the gold standard pharmacological inhibitor, etomoxir [24, 75, 125]. Etomoxir 
inhibits the CPT1 enzyme, which exerts about 80% control over the fatty acid oxidation pathway [23, 
125]. Notably, etomoxir inhibits avocatin B induced cell death indicating that avocatin B’s uptake into the 
mitochondria (chapter 4) is mediated by CPT1. CPT1 exists in 3 isoforms: CPT1A (expressed in the liver, 
kidney, lung, spleen, intestine, pancreas, ovary and fibroblasts), B (expressed in the heart, skeletal muscle, 
testis and brown adipocytes) and C (expressed only in the brain, however its function remains to be 
unknown) [22, 23].   In our studies, CPT1A knockout cells were insensitive to avocatin B treatment 
indicating that CPT1A is essential for leukemia mitochondrial import of avocatin B. In both normal lung 
and kidney cells (Figure 5.1), avocatin B did not cause any reduction in viability further suggesting that it 
may be selective only towards leukemia cells.  
In order for etomoxir to inhibit CPT1, it must first be converted to a CoA ester [126]. This 
mechanism is similar to the entry of fatty acids, which are CoA-esterified by acyl-CoA synthetase [127]. 
Although not formally tested, it is presumed that avocatin B, given its dependence on CPT1 for 
cytotoxicity, is also CoA-esterified by acyl-CoA synthetase prior to entry into mitochondria. As such, 
future studies should examine the role of acyl-CoA synthetase in avocatin B’s mechanistic activity. 
Given that avocatin B inhibits fatty acid oxidation, understanding the in vivo effects of clinically 
used fatty acid oxidation inhibitors may shed light onto avocatin B’s in vivo profile. To date, perhexiline, 
a CPT1 inhibitor, trimetazidine, a 3-ketoacyl-CoA thiolase inhibitor, and ranolazine, a 3-ketoacyl-CoA 
thiolase inhibitor, are approved for human use for the treatment of angina [21]. Inhibition of fatty acid 
oxidation shifts cardiac muscle metabolism towards glucose oxidation to increase myocardial efficiency 
in ischemic conditions [128].  Given these in vivo profiles, it is possible that avocatin B may exert a 
similar profile. 
In chapter 4, we report that avocatin B targets the mitochondria. This is demonstrated through 
cells lacking functional mitochondria displaying insensitivity to avocatin B treatment, through genetic and 
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pharmacological inhibition of CPT1, which facilitates fatty acid transport into the mitochondria, and 
through increased UCP2 expression (chapter 4). Given that the mitochondria is essential for energy 
production and exerts control over cell death, the mitochondria is a feasible target in cancer therapy [129]. 
Mitochondria are implicated in tumorigenesis and tumour progression as cancer cells possess mutations in 
mitochondrial respiratory chain resulting in inefficient ATP production and chromosomal instability 
[130].  In fact, mitochondria in cancer cells are structurally and functionally different from those found in 
normal cells [130, 131]. Cancer cell mitochondria have been reported with a different phospholipid 
mitochondrial membrane composition compared to normal cells [132] as  well as metabolic 
reprogramming (such as fatty acid oxidation in leukemia; chapter 1). The metabolic reprogramming 
observed in cancer cell mitochondria renders them more susceptible to mitochondrial disruption over non-
cancerous cells [133, 134]. Additionally, we report that avocatin B targets leukemia and leukemia stem 
cells through decreases in NADPH resulting in increased levels of ROS (chapter 4). Both breast cancer 
stem cells and leukemia stem cells have been found to express low levels of ROS and higher levels of 
antioxidants compared to blast cells [32, 135]. Given the numerous structural, physiological and 
functional differences in cancer cell mitochondria, targeting the mitochondria is a promising therapeutic 
approach.  
5.2 Mechanism of action 
Inhibition of fatty acid oxidation by avocatin B resulted in ROS-induced apoptosis. Apoptosis 
was mediated by the mitochondrial proteins cytochrome c and AIF, which are commonly released 
following ROS-induced increases in mitochondrial outer membrane permeability [136, 137].  Inhibiting 
fatty acid oxidation by blocking CPT1 with etomoxir resulted in ROS-dependent death of glioma cells 
caused by reduced concentrations of intracellular antioxidants attributed to decreased NADPH [75]. 
Similarly, we demonstrated that avocatin B-induced inhibition of fatty acid oxidation reduced NADPH 
levels and that antioxidant supplementation rescued cells from death.  NADPH is utilized for catabolic 
processes in proliferating cells and is the precursor of reduced glutathione, which counteracts the 
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detrimental effects of ROS [95, 138]. Our observed NADPH decrease (t=5h; Figure 4.11D) preceded 
ROS elevation (t=12h; Figure 4.11E), further confirming the relationship between inhibition of fatty acid 
oxidation, NADPH and ROS-dependent leukemia cell death.  Of note, in our experiments avocatin B 
accumulated in mitochondria and inhibited fatty acid oxidation and reduced NADPH at 10µM whereas 
other studies used etomoxir, which blocks fatty acid entry into mitochondria and reduces NADPH, at 
100µM [24] or 1000µM [75]. Together, these results point to a mechanism where avocatin B enters the 
mitochondria and potently inhibits fatty acid oxidation resulting in reduced NADPH and ROS-induced 
apoptosis.  
5.2.1 Decreased levels of NADPH cause increases in ROS 
Our studies report that the avocado-derived lipid avocatin B was selectively cytotoxic towards 
AML and AML progenitor cells. In contrast, it was not cytotoxic to normal hematopoietic cells (CD34+). 
Mechanistically, avocatin B inhibited fatty acid oxidation resulting in decreased levels of NADPH 
resulting in increased levels of ROS. NADPH is utilized for catabolic processes in proliferating cells and 
is necessary to regenerate reduced glutathione, which counteracts the detrimental effects of ROS [95, 
138].  Notably, Pike et al. (2011) reported that even in the presence of glutamine and glucose, which 
generates NADPH through the pentose phosphate pathway, inhibition of fatty acid oxidation displayed a 
decrease in NADPH [75]. This suggests that NADPH generated from fatty acid oxidation is critical for 
defense against oxidative stress. Coupled with the fact that NADPH cannot pass through the inner 
mitochondrial membrane, NADPH generated from fatty acid oxidation serves as an essential source of 
antioxidants to combat mitochondria specific ROS [26]. Indeed, studies have shown that the 
mitochondrial enzyme IDH2, which regenerates NADPH, is critical towards defending cancer cells 
against oxidative stress and promoting cell survival [75, 139]. Mutations in IDH1 and IDH2 have been 
observed in AML, with reports of low levels of ROS in mice with mutated IDH1 [26, 140]. As such, it is 
speculated that inhibition of IDH1 or IDH2 will cause increases in ROS leading to cell death. In fact, 
decreased expression of IDH2 in fibroblast cell lines resulted in increased ROS levels, mitochondrial 
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damage and DNA fragmentation [141].  Based on these reports, I believe that our observed reports of 
decreased NADPH, directly contribute towards the observed increased levels of ROS in avocatin B 
treated leukemia cells.  
5.2.2 Decreased NADPH and increased levels of ROS cause mitochondria-mediated 
apoptosis 
In our studies, we report that avocatin B induces mitochondria-mediated apoptosis through the 
release of pro-apoptotic proteins cytochrome c and AIF. These reports are supported by disruption of the 
ΔΨm (chapter 4), and subsequent activation of caspases 3 and 7 (chapter 4). Cytochrome c and AIF reside 
in the intermembrane space of the mitochondria, requiring mitochondrial outer membrane 
permeabilization (MOMP) in order to be released [36]. In chapter 4, we report that avocatin B treatment 
increases ROS levels while decreasing NADPH levels. Excessive ROS can induce apoptosis by 
modifying mitochondrial proteins such as mitochondrial permeability transition pore proteins, voltage-
dependent anion channel (VDAC) and adenine nucleotide translocase (ANT), resulting in cytochrome c 
and AIF release [142]. Further, NADPH is required for the regeneration of GSH. Studies have reported 
that mitochondrial GSH redox status is a key modulator of MOMP, and that decreases in GSH result in 
the redox modulation of ANT resulting in the release of cytochrome c and AIF [143, 144]. This coincides 
with our reports that avocatin B decreases both NADPH and GSH (chapter 4) resulting in mitochondria-
mediated apoptosis. 
5.2.3 Avocatin B’s effect on the fatty acid biosynthesis pathway 
Leukemia cells display a metabolic shift from the oxidation of glucose derived carbon sources to 
the oxidation of fatty acids [24]. As such, fatty acids play a pivotal role in providing carbon building 
blocks and growth factors to leukemia cells. In our studies, we report that avocatin B inhibits fatty acid 
oxidation resulting in autophagy and apoptosis activation. In chapter 4, we highlight how autophagy is 
activated as a result of deficiency in cellular building blocks and growth factors.  
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Given that leukemia cells rely on de novo fatty acid synthesis [20, 26], coupled with fact that 
avocatin B related compounds inhibit this pathway, we also explored avocatin B’s effect on the fatty acid 
biosynthesis pathway.  We reported, that supplementation with exogenous palmitate (chapter 4) can 
rescue leukemia cells from avocatin B induced death. Palmitate is the end product of the fatty acid 
biosynthesis pathway and is produced by FASN. FASN has been reported to be upregulated in many 
cancer types, while being expressed at very low levels in most normal human tissues [93]. Therefore, we 
co-incubated avocatin B with the FASN inhibitor orlistat, where it displayed no effect on avocatin B’s 
activity suggesting that its activity is independent of FASN. This indicates that avocatin B and palmitate 
may compete for entry into the mitochondria via CPT1 (Discussed in next section). Next, we further 
excluded the fatty acid biosynthesis pathway through co-incubation with malonyl-CoA, acetyl-CoA 
(acetyl-CoA carboxylase end products) and oleic acid (SCD1 end product), and showed that neither 
treatments could rescue cells from avocatin B induced cell death. These results suggest that avocatin B’s 
activity is independent of the fatty acid biosynthesis pathway, and is only reliant on the uptake and 
oxidation of fatty acids in the mitochondria.  
Interestingly, accumulation of malonyl-CoA, an intermediary fatty acid metabolite, can be 
cytotoxic to cells. Indeed, treatment of TEX cells with high concentration of malonyl-CoA reduced cell 
viability (chapter 5). Malonyl-CoA is a cytotoxic reversible inhibitor of CPT1 which prevents newly 
synthesized fatty acids from undergoing oxidation [92, 93]. Accumulation of malonyl-CoA, results in 
apoptosis onset as a result of the activation of pro-apoptotic proteins BNIP3, TRAIL and DAPK2 [93]. 
Similarly, we report that avocatin B induces autophagy activation through BNIP3 expression (chapter 4), 
which is involved in both autophagy and apoptosis onset. Future studies will need to explore the link 
between fatty acid oxidation, autophagy and apoptosis onset.        
5.2.4 Palmitate supplementation rescues TEX cells from avocatin B induced cell death 
In chapter 4, we report that palmitate supplementation rescues TEX cells from avocatin B 
treatment. These results present a number of associated questions. We reported that co-incubation with 
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avocatin B and palmitate display a reduction in fatty acid oxidation and reduced NADPH levels. Given 
that long-term palmitate supplementation rescues TEX cells, avocatin B may in fact compete with 
palmitate for entry into the mitochondria via CPT1. This mode of action would be similar to that of other 
drugs that compete with endogenous ligands to alter cellular responses, as is the case with tamoxifen that 
competes with estrogen to block proliferation [145] or anastrozole that competes for the aromatase 
inhibitor in breast and ovarian cancer treatments [146].   Studies exploring this potential competitive 
mechanism have yet to be performed, as such should be explored in future studies. 
5.2.5 Oxidation of odd-numbered lipids 
Avocatin B is a 1:1 ratio of two 17-carbon lipids derived from methanol extracted avocado pear 
seeds (Persea gratissima) [84]. Odd-numbered carbons are rare, not produced endogenously and obtained 
only from dietary sources [147, 148]. Moreover, they are not efficiently or preferentially oxidized. For 
example, mice fed diets containing radiolabelled odd and even-numbered fatty acids only accumulate 
odd-numbered fatty acids in adipose tissue (i.e., C15 and 17) [149]; odd-numbered fatty acids show 
consistent adipose accumulation [147, 150, 151]. In humans, lipids of 13, 15 and 17 carbon lengths are 
used as serum and adipose tissue biomarkers of dietary fat intake, as these fatty acids are more slowly 
catabolized compared to even-numbered fatty acids [148, 152]. Although they undergo the same pathway 
of oxidation, the terminal step of odd-numbered fatty acid oxidation produces 1 acetyl-coA and 1 
propionyl-CoA molecule whereas even-numbered fatty acids produce 2 acetyl-coA molecules [153]. 
Propionyl-CoA can then be converted to methylmalonyl-CoA by propinyl-CoA carboxylase and vitamin 
B12, at the expense of 1 ATP, which is in turn converted to succinyl-CoA that can enter the TCA cycle 
[151]. Since this alternate pathway requires energy and delays overall ATP production, the decreased 
metabolic activity (i.e., reduced acetyl-CoA production and/or decreased entry of fatty acid byproducts 
into the TCA cycle) likely explains our observed decrease in NADPH. As such, reduced NADPH not 
only results in elevated ROS but also indicates a decrease in overall metabolic activity. Thus, a novel 
pathway by which fatty acid oxidation can be inhibited in leukemia cells is by the odd-numbered carbon 
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lipid, avocatin B stalling or rendering less efficient the fatty acid oxidation pathway. This highlights a 
novel strategy to induce selective leukemia cell death by which preferential mitochondrial localization of 
avocatin B reduces leukemia cell metabolism and NADPH to increase ROS resulting in cell death.  
5.2.6 Lipotoxicity 
Alternatively, mitochondrial accumulation of fatty acids could have lipotoxic effects.  When in 
excess, fatty acids can accumulate inside the mitochondrial matrix where they are deprotonated, as a 
result of the proton gradient, creating fatty acid anions. These are converted by ROS into lipid peroxides 
that in turn cause damage to mitochondrial DNA, lipids and proteins within the mitochondrial matrix 
[154]. However, the generation of lipotoxic products requires ROS [155], therefore; avocatin B 
accumulation by itself would be insufficient to impart lipotoxicity. Thus once inside the mitochondria, 
avocatin B or avocatin B derivatives may be converted to lipotoxic byproducts and contribute to death but 
only after sufficient ROS production (i.e., following avocatin B-induced inhibition of fatty acid 
oxidation). In further support of this explanation, avocatin B increased UCP2 levels, consistent with 
mitochondrial accumulation [109], but this was observed only after 48 hours of treatment (i.e., UCP2 
expression follows our observed ROS elevation). In fact, a prevailing hypothesis is that the function of 
UCP upregulation is to drive fatty acid anions outside the mitochondrial matrix to reduce lipotoxicity 
[109, 156]. Thus, mitochondrial accumulation may contribute to death through lipotoxicity but this is not 
the underlying mechanism of avocatin B’s activity.  
5.3 Avocatin B induces autophagy 
We reported that the avocado-derived lipid avocatin B inhibits fatty acid oxidation that was 
followed by ROS-mediated leukemia and leukemia stem cell apoptosis [111]. Here, we report new 
evidence highlighting autophagy as an essential intermediate step in avocatin B-induced selective 
leukemia cell apoptosis. 
 In this study, we show that autophagy was critical to avocatin B’s toxicity. We demonstrated that 
autophagy was activated and that autophagy proteins were functionally important to avocatin B-induced 
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death. Given these findings, it seems likely that autophagy activation is due to prolonged deprivation of 
essential growth factors (e.g. fatty acid-derived metabolites and NADPH) that leads to the generation of 
ROS. Starvation is one of the most well-studied conditions that results in autophagy activation [46, 157]. 
Most autophagy stimuli converge at the protein complex mTORC1 which serves as a stimuli sensor, 
detecting nutrient and growth factor availability [45, 46]. Given that leukemia cells possess an abnormal 
mitochondrial phenotype characterized by a greater demand for fatty acid substrates [29, 31], we propose 
that inhibiting fatty acid oxidation activates autophagy by causing a significant deficiency in essential 
cellular building blocks. Similar to our previous study demonstrating that avocatin B-induced apoptotic 
cell death characterized by caspase activation and AIF release [111], serum deprivation in hippocampal 
HT22 neurons activated autophagy that resulted in caspase 3 and AIF-mediated apoptosis [39]. Moreover, 
we previously showed that avocatin B’s activity was ROS-dependent (as measured by DHE and DCF-
DA), as leukemia cells co-incubated with anti-oxidants block its activity[111]. Thus, it is likely that 
avocatin B-induced autophagy is activated by ROS following serum starvation. Indeed, accumulating 
evidence indicates that ROS plays an essential role in the activation of autophagy and that the 
mitochondria is the main source of ROS [120, 157, 158].  
 We have shown that avocatin B-induced apoptosis was characterized by release of the 
mitochondrial proteins cytochrome c and AIF [111].  In this study, we show that AML cells with 
significantly reduced autophagy proteins Atg7 and p62 are insensitive or increasingly sensitive to 
avocatin B’s cytotoxicity, respectively.  This indicates that autophagy plays a functional role in avocatin 
B’s death inducing mechanism. As such, avocatin B’s activation of autophagy must be involved in the 
induction of mitochondrial apoptosis. Similar to avocatin B, mitochondrial target drugs induce both 
autophagic and apoptotic responses. Arsenic trioxide and obatoclax induces both autophagy and apoptosis 
in leukemia cells [159, 160]; rottlerin induces both processes in prostate cancer cells [161].  Finally, 
APO866 and FK866 induce both autophagy and apoptosis as a result of NAD depletion in cells from 
various hematological malignancies, including AML [162].  Avocatin B reduced NADPH and NAD and 
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similar to APO866 and FK866’s activity, autophagy is activated following an induced deficiency of an 
essential cellular growth factor.  
 Avocatin B-mediated leukemia cell death is dependent on the induction of autophagy. As such, 
there is cross-talk between autophagy and apoptosis signaling pathways. Additional studies are needed to 
further elucidate the mechanism of this crosstalk following avocatin B treatment. In cancer cells, the 
combined activation of autophagy and apoptosis has been observed through DRAM1 (damage –regulated 
autophagy modulator 1), which is activated by p53 [42, 44]; Beclin 1 has been linked to p53 stability and 
function [50]. p53 is also linked to autophagy induction through the pro-apoptotic PUMA, which induces 
cytochrome c release [44]. In addition, Atg12 promotes intrinsic apoptosis through inactivation of the 
anti-apoptotic Bcl-2 family members Bcl-2 and Mcl-1 [51]. Future studies will evaluate the role of Beclin 
and p53 in avocatin B’s activity to further elucidate the means by which inhibition of fatty acid oxidation 
activates autophagy to induce apoptosis in leukemia.  
  In conclusion, avocatin B activates autophagy in response to increased levels of ROS as a result 
of fatty acid oxidation impairment. Autophagy is essential for avocatin B’s anti-leukemia activity which 
acts through the release of mitochondrial pro-apoptotic proteins cytochrome c and AIF. Given the 
observed findings, we highlight a novel mechanistic link between inhibition of fatty acid oxidation, 
autophagy and apoptosis.  
5.4 Avocatin B as a novel therapy for AML 
A major long-term goal of this project involves assessing avocatin B’s pre-clinical efficacy for its 
potential as a novel AML chemotherapeutic. Currently, avocatin B is not marketed for any indications, 
however our findings suggest that it can have anti-cancer effects.  
 Few compounds that inhibit fatty acid oxidation are currently approved for clinical use [95]. 
CPT1 inhibitors such as etomoxir and perhexiline are associated with hepatoxicity [163] and 
neurotoxicity [164], respectively, and are not approved for clinical use in North America. Other inhibitors 
such as trimetazidine, which inhibits 3-ketoacyl-CoA thiolase, an enzyme involved in fatty acid 
 70 
 
catabolism and ranolazine, which blocks late sodium currents, have had clinical success for the treatment 
of angina [165, 166]. None of these compounds are approved for use in AML or other hematological 
malignancies.  Future studies are needed to asses avocatin B’s pharmacology and pharmacokinetics; 
however, initial assessment of avocatin B’s physicochemical properties suggests favorable tissue 
distribution. In particular, it possesses a high estimated partition coefficient (LogP = 8.9 [85]) indicating 
that it will accumulate in lipid-rich tissues such as adipose tissue and bone marrow. Given that LSCs 
reside in bone marrow, this could significantly enhance avocatin B’s therapeutic efficacy.  
 If avocatin B were to become a chemotherapeutic, we must first consider routes of administration. 
Based on Lipinski’s rule of five, avocatin B would be unsuitable for oral formulation due to its 6 
hydrogen bond donors, its LogP of 8.9, and its molecular weight of 570.88g/mol [85].  As such, avocatin 
B would need to be administered intravenously (IV). IV administration is not uncommon for the 
treatment of AML as current therapy consisting of cytarabine and daunorubicin are administered IV [1].   
 Although no specific pharmacokinetic data is available, mice treated with an ethanol avocado 
pear seed extract (Persea Americana) had an LD50 of 1200.75mg/kg body weight [167]. Nonetheless, 
future studies are needed to test the pharmacokinetics and safety of avocatin B prior to entering human 
trials. 
5.5 Limitations 
Avocatin B was initially identified in an 800 compound drug screen of the TEX leukemia cell 
line. A limitation of our study was the number of cell lines used to test and validate our reported results. 
When the US National Cancer Institute screens for novel anticancer drugs, it involves 60 different cells 
lines from 9 different types of tumours [168]. Unfortunately, we do not have access to that many different 
cell lines. Additionally, our drug displays activity in TEX, an AML cell line with LSC properties. To 
date, cell lines with similar properties are publicly unavailable through outlets such as ATCC. To 
compensate for this, we used avocatin B at higher concentrations in less sensitive cell lines to observe an 
effect (ie. OCI-AML2 cells). This was performed to validate avocatin B’s mechanistic effects. Given that 
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we reported avocatin B’s efficacy in primary AML patient samples as well as in mouse 
xenotransplantation models, we do not feel that the lack of cell line data mitigate the significance of our 
findings.   
 Another limitation is the number of primary AML patient samples tested. In our studies, we 
report avocatin B’s efficacy in 9 patient samples through the annexin V/PI viability assay and colony 
formation assays. Similar drug discovery studies have reported the use of ~20 primary AML patient 
samples [28, 114]. Unfortunately, our lab does not have direct access to patient samples. Through 
collaboration with Princess Margaret Cancer Hospital, we have been fortunate to obtain frozen aliquots of 
the primary AML samples that were tested in this study.   
5.6 Conclusions 
Given the need for the discovery of novel anti-leukemia and anti- leukemia stem cell drug 
candidates, the findings in this thesis have provided new insight for treatment strategies. Here, we report 
the discovery of avocatin B, an avocado-derived lipid, which selectively targets AML and leukemia stem 
cells through the inhibition of fatty acid oxidation. Avocatin B’s mechanism of action is unique to current 
AML treatment strategies, making it an ideal target for future AML therapy. Future studies will need to 
further elucidate avocatin B’s molecular target to characterize the cross talk that is observed between 
autophagy, apoptosis and fatty acid oxidation. Additionally, avocatin B’s safety and pharmacokinetic 
properties will need to be assessed in mouse models in order to validate its pre-clinical efficacy and 
safety. In conclusion, the findings of this thesis, has provided the groundwork to establishing avocatin B’s 
pre-clinical efficacy as a potential AML therapeutic and have elucidated a novel therapeutic strategy for 
the treatment of AML.  
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Appendix A: Research activity resulting from this program 
PUBLICATIONS AND MANUSCRIPTS 
Provisional patent application. Filed Oct 2014. Inventors: Spagnuolo PA, Schimmer AD, Lee EA 
 
Lee EA, Angka L, Kreinin, E, McMillan EM, Giaever G, Quadrilatero J, Schimmer AD, Spagnuolo PA. 
Autophagy is required for the activation of apoptosis following inhibition of fatty acid oxidation. In 
preparation. 
 
Lee EA, Angka L, Rota SG, Hurren R, Wang XM, Gronda M, Bernard D, Minden M, Mitchell A, Joseph 
JW, Datti A, Wrana J, Quadrilatero J, Schimmer AD, Spagnuolo PA. Targeting mitochondria with 
avocatin B induces selective leukemia cell death. Cancer Research. CAN-14-2676. Revisions Pending. 
2014. 
 
Nafissi N, Alqawlaq S, Lee EA, Foldvari M, Spagnuolo PA, Slavcev RA. DNA ministrings: highly safe 
and effective gene delivery vectors. Mol Ther Nucleic Acids. May 27 2014. 
 
Angka L, Lee EA, Rota SG, et al. Glucopsychosine increases cytosolic calcium to induce calpain-
mediated apoptosis of acute myeloid leukemia cells. Cancer letters. Mar 12 2014. 
 
PRESENTATIONS 
Oral presentation. Inhibition of fatty acid oxidation with avocatin B selectively targets AML cells and 
leukemia stem cells. American Society of Hematology Meeting 2014. San Francisco, CA. Dec 2014 
 
Guest lecture: Nutrition, metabolism and body temperature regulation. PHARM111 - Systems Approach 
to the Study of the Human Body 2. University of Waterloo, Waterloo, ON. July 2014 
 
Oral presentation. AVO: a novel inhibitor of fatty acid oxidation that induces selective leukemia cell 
death. 3-Minute Thesis Competition. University of Waterloo, Waterloo, ON. Mar 2014 
 
Poster. 45 - Avocatin B is a novel inhibitor of fatty acid oxidation that induces selective leukemia cell 
death. Till and McCulloch Meetings 2014. Ottawa, ON. Oct 2014 
 
Poster. AVO: a novel inhibitor of fatty acid oxidation that induces selective leukemia cell death 
Institute for comparative cancer investigation 2014. Guelph, ON. May 2014 
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